









INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07D 211/76, 211/52, 401/12, A61K 31/445	A1	(11) International Publication Number: WO 99/26924 (43) International Publication Date: 3 June 1999 (03.06.99)
(21) International Application Number: PCT/US98/23255 (22) International Filing Date: 18 November 1998 (18.11.98) (30) Priority Data: 08/975935 21 November 1997 (21.11.97) US (71) Applicant: SCHERING CORPORATION [US/US]; 2000 Galloping Hill Road, Kenilworth, NJ 07033 (US). (72) Inventors: REICHARD, Gregory, A.; 4 Bahama Road, Morris Plains, NJ 07950 (US). ALAIMO, Cheryl, A.; 218 Onizuka Court, Somerset, NJ 08873 (US). SHIH, Neng-Yang; 1 Maple Drive, North Caldwell, NJ 07006 (US). TING, Pauline, C.; 74 Delwick Lane, New Providence, NJ 07974 (US). CARRUTHERS, Nicholas, I.; 358 West End Avenue, North Plainfield, NJ 07060 (US). LAVEY, Brian, J.; Apartment H-10, 25 Hickory Place, Chatham, NJ 07928 (US). (74) Agents: MAGATTI, Anita, W. et al.; Schering-Plough Corporation, Patent Dept., K-6-1 1990, 2000 Galloping Hill Road, Kenilworth, NJ 07033-0530 (US).		(81) Designated States: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CZ, EE, GD, GE, HR, HU, ID, IL, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UZ, VN, YU, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>

(54) Title: SUBSTITUTED OXIMES AS NEUROKININ ANTAGONISTS



(57) Abstract

Compounds within the genus represented by structural formula (I) or a pharmaceutically acceptable salt thereof, wherein: T is substituted phenyl or substituted pyridyl; R¹ is H, methyl, ethyl, -CH₂CN, -CH₂C(O)NH₂, -(CH₂)₃SO₃H, -CH₂C(O)NHCH₃, -CH₂C(O)NHOH, -CH₂C(O)NHOCH₃, -CH₂C(O)NHCH₂CN, -CH₂F, -CH₂C(O)NHCH₂SO₃H, (a), (b), (c), (d) or (e); R⁴ is methyl or ethyl; and Z is substituted piperidiny.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

5

10 **SUBSTITUTED OXIMES AS NEUROKININ ANTAGONISTS****BACKGROUND OF THE INVENTION**

 The present invention relates to a genus of substituted oximes useful as antagonists of tachykinin receptors, in particular as
15 antagonists of the neuropeptides neurokinin-1 receptor (NK₁) and/or neurokinin-2 receptor (NK₂) and/or neurokinin-3 receptor (NK₃).


 Neurokinin receptors are found in the nervous system and the circulatory system and peripheral tissues of mammals, and therefore are involved in a variety of biological processes. Neurokinin receptor
20 antagonists are consequently expected to be useful in the treatment or prevention of various mammalian disease states, for example asthma, cough, chronic obstructive pulmonary disease (COPD), bronchospasm, emesis, neurodegenerative disease, ocular disease, inflammatory diseases such as arthritis, central nervous system conditions such as
25 migraine and epilepsy, nociception, psychosis and various gastrointestinal disorders such as Crohn's disease.

 In particular, NK₁ receptors have been reported to be involved in microvascular leakage and mucus secretion, and NK₂ receptors have been associated with smooth muscle contraction, making
30 NK₁ and NK₂ receptor antagonists especially useful in the treatment and prevention of asthma.

 Some NK₁ and NK₂ receptor antagonists have previously been disclosed: arylalkylamines were disclosed in U.S. Patent 5,350,852, issued September 27, 1994, and spiro-substituted azacycles were
35 disclosed in WO 94/29309, published December 22, 1994.

 U.S. 5,696,267 discloses compounds represented by the generic structure

- 2 -



or a pharmaceutically acceptable salt thereof, wherein:

a is 0, 1, 2 or 3;

R is H, C₁₋₆ alkyl, -OH or C₂₋₆ hydroxyalkyl;

5 A is an optionally substituted oxime, hydrazone or olefin;

X is a bond, -C(O)-, -O-, -NR⁶-, -S(O)_e-, -N(R⁶)C(O)-, -C(O)N(R⁶)-, -OC(O)NR⁶-, -OC(=S)NR⁶-, -N(R⁶)C(=S)O-, -C(=NOR¹)-, -S(O)₂N(R⁶)-, -N(R⁶)S(O)₂-, -N(R⁶)C(O)O- or -OC(O)-;

b, d and e are independently 0, 1 or 2;


10 T is H, phthalimidyl, aryl, heterocycloalkyl, heteroaryl, cycloalkyl or bridged cycloalkyl;

Q is -SR⁶, -N(R⁶)(R⁷), -OR⁶, phenyl, naphthyl or heteroaryl;

15 R^{6a}, R^{7a}, R^{8a}, R^{9a}, R⁶ and R⁷ are H, C₁₋₆ alkyl, C₂₋₆ hydroxyalkyl, C₁₋₆ alkoxy-C₁₋₆ alkyl, phenyl or benzyl; or R⁶ and R⁷, together with the nitrogen to which they are attached, form a ring;

R^{9a} is R⁶ or -OR⁶;

Z is morpholinyl, optionally N-substituted piperazinyl, optionally



g is 0-3 and h is 1-4, provided the sum of h and g is 1-7;


20 wherein aryl, heterocycloalkyl, heteroaryl, cycloalkyl and bridged cycloalkyl groups are optionally substituted.

We have found that certain compounds within that generic structure show surprisingly greater activity as neurokinin antagonists than those previously specifically disclosed.

25

SUMMARY OF THE INVENTION

Compounds of the present invention are represented by the formula I




- 3 -

or a pharmaceutically acceptable salt thereof, wherein:

T is R²-phenyl or R³-pyridyl;

R¹ is H, methyl, ethyl, -CH₂CN, -CH₂C(O)NH₂, -(CH₂)₃SO₃H, -CH₂C(O)NHCH₃, -CH₂C(O)NHOH, -CH₂C(O)NHOC(CH₃)₃, -CH₂C(O)NHCH₂CN, -CH₂F, -CH₂C(O)NHCH₂SO₃H,

5




R² is 2-3 substituents independently selected from the group consisting of chloro, methyl and methoxy;

R³ is 2 to 3 substituents independently selected from the group
10 consisting of chloro and methyl;

R⁴ is methyl or ethyl; and

Z is



20



Preferred are Z-isomers of compounds of formula I.

Preferred are compounds of formula I wherein T is R²-phenyl, with compounds wherein R² is two chloro substituents, two methyl

- 4 -


substituents (preferably 3,5-dichloro or 3,5-dimethyl), or two methoxy and one methyl substituent (i.e., 3,5-methoxy-4-methyl) being more preferred; compounds wherein R² is two chloro groups are especially preferred.

Also preferred are compounds of formula I wherein R¹ is

- 5 methyl, -CH₂F, -CH₂CN, -(CH₂)₃SO₃H,  or , with methyl being more preferred.

R⁴ is preferably methyl.

Another group of preferred compounds is that wherein Z is ,



This invention also relates to the use of a compound of formula I in the treatment of asthma, cough, chronic obstructive pulmonary disease (COPD), bronchospasm, emesis, neurodegenerative disease, ocular disease, inflammatory diseases such as arthritis, central nervous system conditions such as migraine and epilepsy, nociception, psychosis, and various gastrointestinal disorders such as Crohn's disease.



In another aspect, the invention relates to a pharmaceutical composition comprising a compound of formula I in a pharmaceutically acceptable carrier. The invention also relates to the use of said



- 5 -


pharmaceutical composition in the treatment of asthma, cough, chronic obstructive pulmonary disease (COPD), bronchospasm, emesis, neurodegenerative disease, ocular disease, inflammatory diseases such as arthritis, central nervous system conditions such as migraine and epilepsy, nociception, psychosis, and various gastrointestinal disorders such as Crohn's disease.

DETAILED DESCRIPTION

In the structural formulas shown throughout the specification and claims, hydrogen atoms may be understood, e.g., the partial structure

10  is the same as , and methyl groups may appear as a

line, e.g.,  is the same as . Some formulas may include a methyl group shown as a line, and the point of attachment to another atom shown as a line through which a wavy line is drawn, i.e.,



15 Compounds of formula I can have at least one asymmetric carbon atom and all isomers, including diastereomers, enantiomers and rotational isomers, as well as E and Z isomers of the oxime, hydrazone and olefin groups, are contemplated as being part of this invention. The invention includes d and l isomers in both pure form and in admixture, including racemic mixtures. Isomers can be prepared using conventional techniques, either by reacting optically pure or optically enriched starting materials or by separating isomers of a compound of formula I.

20 Those skilled in the art will appreciate that for some compounds of formula I, one isomer will show greater pharmacological activity than other isomers.

25 Compounds of the invention have at least one amino group which can form pharmaceutically acceptable salts with organic and inorganic acids. Examples of suitable acids for salt formation are hydrochloric, sulfuric, phosphoric, acetic, citric, oxalic, malonic, salicylic, 30 malic, fumaric, succinic, ascorbic, maleic, tartaric, methanesulfonic and other mineral and carboxylic acids well known to those in the art. The salt is prepared by contacting the free base form with a sufficient amount of the

- 6 -

desired acid to produce a salt. The free base form may be regenerated by treating the salt with a suitable dilute aqueous base solution such as dilute aqueous sodium bicarbonate. The free base form differs from its respective salt form somewhat in certain physical properties, such as solubility in polar solvents, but the salt is otherwise equivalent to its respective free base forms for purposes of the invention.


Certain compounds of the invention are acidic (e.g., those compounds which possess a carboxyl group). These compounds form pharmaceutically acceptable salts with inorganic and organic bases.

Examples of such salts are the sodium, potassium, calcium, aluminum, gold and silver salts. Also included are salts formed with pharmaceutically acceptable amines such as ammonia, alkyl amines, hydroxyalkylamines, N-methylglucamine and the like.

Compounds of formula I can be prepared using methods well known to those skilled in the art, for example by procedures disclosed in WO 96/34857. The skilled artisan will recognize that other procedures may be applicable, and that the procedure may be suitably modified to prepare other compounds within the scope of formula I.

Compounds of formula I as defined above can be prepared as shown in the following reaction scheme relating to the broader scope of compounds disclosed in WO 96/34857. In the reaction scheme, the variables are as defined above for the PCT application:

Step 1:




In step 1, a compound of formula 47A, wherein Q is as defined above, is reacted with a base such as lithium diisopropylamide (LDA), KHMDS or KH in an inert organic solvent such as THF or DME to generate a dianion. An acid chloride, ester or amide of formula 46A, 46B, or 46C is added to give a ketone of formula 48. Preferable reaction temperatures ranges from -78°C to 30°C.


Alternatively, compounds of formula 48 can be generated by the reaction of a compound of formula 46, preferably 46C, with a metallated

- 7 -


species of formula QCH_2Mt where Mt is a metal, such as lithium or $MgHal$, wherein "Hal" is halogen. The metallated species QCH_2Mt can be generated by conventional procedures, such as treatment compounds of formula QCH_2Hal with Mg or by treating QCH_3 with an organolithium base.

Step 2:


In step 2, for compounds disclosed in the PCT application wherein R is not hydrogen, the ketone 48 is reacted with a suitable base, such as LDA or KH in an inert organic solvent such as THF. For compounds wherein R is alkyl or hydroxyalkyl, a compound $R-R^{17''}$, wherein $R^{17''}$ is leaving group such as Br , I or triflate is added. For compounds of the PCT application wherein R is OH , an appropriate oxidizing agent such as dimethyldioxirane or Davis reagent is added. Preferable reaction temperatures range from -78° to $50^\circ C$. For compounds of the present invention, corresponding to compounds of the PCT application wherein R is H , the ketone 48 is used directly in Step 3.

Step 3:

In step 3, ketone 49 is reacted with a base such as LDA in a solvent such as THF, then an olefin of formula 50 is added, wherein $R^{17''}$ is as defined above, to give the adduct 51. Preferable reaction temperatures range from $-78^\circ C$ to $60^\circ C$.

Step 4:


In step 4, ketone 51 is reacted with HA' , wherein A' is $NH-OR^1$, in an organic solvent such as pyridine or ethanol at a temperature from $25^\circ C$ to $150^\circ C$ to give a compound of formula 52.

Step 5:

- 8 -


In step 5, a compound of formula 52 is oxidized by ozonolysis to give an aldehyde of formula 53. Suitable organic solvents include EtOAc, CH₃OH, ethanol, CH₂Cl₂ or the like. Preferable reaction temperatures are from -78 to 0°C.

5 Step 6:



In step 6, an aldehyde of formula 53 is reacted with a compound of formula Z-H, wherein Z is as defined above. The reaction is preferably carried out with a suitably substituted amine (as its acid salt e.g. HCl or maleate or as its free base) and a hydride source such as NaBH₃CN or sodium triacetoxyborohydride in a suitable solvent (e.g. CH₃OH, CH₃CH₂OH, or CF₃CH₂OH for NaBH₃CN, or THF, 1,2-dichloroethane, CH₃CN or CF₃CH₂OH for triacetoxyborohydride), with 3A sieves to obtain the desired product. Any suitable temperature can be used with preferable temperatures between 0°C and 25°C.

Alternatively, a compound of formula I can be prepared from 51 by the following reaction scheme, wherein the variables are as defined for the cited PCT application:




Compound 51 is oxidized to a compound of formula 54 under conditions similar to those described for step 5 above. The aldehyde of formula 54 is reacted with a compound of formula Z-H in a manner similar to that described in Step 6, and the resultant ketone is then reacted with a compound of the formula HA' as described above in Step 4 to obtain the compound of formula I.

Reactive groups not involved in the above processes can be protected during the reactions with conventional protecting groups which can be removed by standard procedures after the reaction. The following Table 1 shows some typical protecting groups:

- 9 -

Table 1

Group to be Protected	Group to be Protected and Protecting Group
-COOH	-COOalkyl, -COObenzyl, -COOphenyl, -COOallyl
>NH	$\begin{matrix} \diagup \text{NCOalkyl}, & \diagup \text{NCObenzyl}, & \diagup \text{NCOphenyl}, \\ \diagdown \text{NCH}_2\text{OCH}_2\text{CH}_2\text{Si}(\text{CH}_3)_3 & \diagdown \text{NC}(\text{O})\text{OC}(\text{CH}_3)_3, \\ \diagdown \text{N-benzyl}, & \diagdown \text{NSi}(\text{CH}_3)_3, & \begin{matrix} \text{CH}_3 \\ \\ \diagdown \text{NSi-C}(\text{CH}_3)_3 \\ \\ \text{CH}_3 \end{matrix} \end{matrix}$
-NH ₂	
-OH	$\begin{matrix} -\text{OCH}_3, -\text{OCH}_2\text{OCH}_3, -\text{OSi}(\text{CH}_3)_3, -\text{OSi}(\text{CH}_3)_2\text{C}(\text{CH}_3)_2, \\ -\text{Oallyl} \text{ or } -\text{OCH}_2\text{phenyl} \end{matrix}$

Compounds of formula I have been found to be antagonists of NK₁ and/or NK₂ and/or NK₃ receptors, and are therefore useful in treating conditions caused or aggravated by the stimulation of said receptors.

The present invention also relates to a pharmaceutical composition comprising a compound of formula I and a pharmaceutically acceptable carrier. Compounds of this invention can be administered in conventional oral dosage forms such as capsules, tablets, powders, cachets, suspensions or solutions, or in injectable dosage forms such as solutions, suspensions, or powders for reconstitution. The pharmaceutical compositions can be prepared with conventional excipients and additives, using well known pharmaceutical formulation techniques. Pharmaceutically acceptable excipients and additives include non-toxic and chemically compatible fillers, binders, disintegrants, buffers, preservatives, anti-oxidants, lubricants, flavorings, thickeners, coloring agents, emulsifiers and the like.

The daily dose of a compound of formula I for treating asthma, cough, bronchospasm, inflammatory diseases, migraine, nociception and gastrointestinal disorders is about 0.1 mg to about 20 mg/kg of body weight per day, preferably about 0.5 to about 15 mg/kg. For


- 10 -

an average body weight of 70 kg, the dosage range is therefore from about 1 to about 1500 mg of drug per day, preferably about 50 to about 200 mg, more preferably about 50 to about 500 mg/kg per day, given in a single dose or 2-4 divided doses. The exact dose, however, is determined by the attending clinician and is dependent on the potency of the compound administered, the age, weight, condition and response of the patient.

Following are examples of preparing starting materials and compounds of formula I. As used herein, Me is methyl, Bu is butyl, Br is bromo, Ac is acetyl, Et is ethyl and Ph is phenyl.


Preparation 1

1-[[[(3,5-bis(trifluoromethyl)phenyl)methoxy]-3-(3,4-dichlorophenyl)-5-(4-hydroxy-4-phenyl-1-piperidiny)-2-pentanone



Treat a solution of (*cis*)-[[[(3,5-bis(trifluoromethyl)phenyl)methoxy]-methyl]-4-(3,4-dichlorophenyl)-4-hydroxy-4-phenyl-1-piperidinebutanol (2.0 g, 3.08 mmol) in acetone (90 mL, 0 °C) with Jones reagent (9 mL of H₂CrO₄ in H₂SO₄ (ca. 8 M)). Stir the light orange suspension at 0°C for 1 h, then partition between CH₂Cl₂ (150 mL) and saturated aqueous NaHCO₃ (150 mL). Extract the aqueous layer with CH₂Cl₂ (3 x 150 mL), back extract the combined organic layers with saturated aqueous NaHCO₃ (150 mL), dry (Na₂SO₄) and concentrate to give 1.94 g crude product. Purify by silica gel chromatography (column: 4 cm x 15 cm; eluant: EtOAc:hexane: triethylamine (66:33:2)) to obtain 1.64 g (2.53 mmol, 82%) of the title compound as a colorless foam. HRMS (FAB, M+H⁺): *m/e* calc'd for [C₃₁H₃₀NO₃Cl₂F₆]⁺: 648.1507, found 648.1496.

Preparation 2




Dissolve 4-aminomethyl-piperidine (30.00 g, 0.263 mol) in CH₃OH (500 mL), cool to -30°C under N₂, add di-*t*-butyl dicarbonate (38.23 g, 0.175 mol) in CH₃OH (100 mL) dropwise, warm slowly to 23°C and stir for 16 h. Concentrate, add CH₂Cl₂ (700 mL), wash with saturated aqueous NaCl (2x200 mL), dry organic solution (MgSO₄), filter and concentrate to


- 11 -

give 36.80 g of a 86:14 mixture of the title compound and 1,1-dimethylethyl 4-[(1,1-dimethylethoxyloxycarbonyl)methyl]-1-piperidinecarboxylate.

Step 2A:




- 5 Dissolve the product (19.64 g, 0.0916 mol, 22.84 g of the mixture) of Step 1 in dry CH_2Cl_2 (350 mL) and cool to 0°C under N_2 . Add pyridine (10.87 g, 11.1 mL, 0.137 mol) then chloroaleryl chloride (15.63 g, 13.0 mL, 0.101 mol), warm slowly to 23°C and stir for 16 h. Add saturated aqueous NH_4Cl (300 mL), separate layers and extract with CH_2Cl_2
- 10 (2x250 mL). Dry combined organic extracts (MgSO_4), filter and concentrate. Purify by chromatography (1000 mL of flash silica gel; eluant: 1:1 EtOAc:hexane, then EtOAc). Combine appropriate fractions and concentrate to give 25.36 g (0.0762 mol, 84%) as a colorless oil. MS (Cl/ CH_4): m/e 333 (M+1)




Treat the product of Step 1 in a procedure similar to that described for Step. 2A, using chlorobutyl chloride. MS (FAB): m/e 319 (M+1)

Step 3:




- 20 Wash NaH (3.84 g, 0.160 mol, 6.40 g of 60 wt%) with hexane (25 mL), suspend in dry THF (150 mL) and cool to 0°C under N_2 . Add the product (25.35 g, 0.0762 mol) of Step. 2A in dry THF (150 mL) dropwise. Stir at 23°C for 30 mins, reflux for 6 h, and stir at 23°C for 16 h. Cool to 0°C and add water (150 mL) and 1 N HCl (150 mL). Concentrate and
- 25 extract with EtOAc (3x200 mL). Wash combined organic extracts with saturated aqueous NaCl, dry (MgSO_4), filter and concentrate. Purify by chromatography (600 mL of flash silica gel; eluant: 5% $\text{CH}_3\text{OH}-\text{CH}_2\text{Cl}_2$). Combine appropriate fractions and concentrate to give 21.62 g (0.0729 mol, 96%) of the title compound as a yellow oil. MS (FAB): m/e 297 (M+1)




Treat the product of Step 2B in a procedure similar to that described for Prep. 2A. MS (FAB): m/e 283 (M+1).


- 12 -




Combine the product (1.50 g, 5.06 mmol) of Prep. 2A and Lawesson reagent (1.13 g, 2.78 mmol) in dry THF (20 mL) under N₂. Stir at 23°C for 20 h. Concentrate and purify by chromatography (200 mL of flash silica gel; eluant: 1:3 EtOAc:hexane, 1:2 EtOAc:hexane, then 1:1 EtOAc:hexane). Combine appropriate fractions and concentrate to give 1.30 g (4.16 mmol, 82%) as a green oil. MS (FAB): m/e 313 (M+1).



Dissolve the product (2.50 g, 8.43 mmol) of Prep. 2A in dry THF (30 mL), add borane-DMS (16.9 mL of 2.0 M in THF, 33.74 mmol) and reflux for 20 h. Cool to 0°C and add CH₃OH (20 mL). Concentrate, add EtOH (50 mL) and K₂CO₃ (4.66 g, 33.74 mmol). Reflux for 4 h and cool to 23°C. Add water (100 mL), concentrate and extract with CH₂Cl₂ (4x50 mL). Dry combined organic extracts (MgSO₄), filter and concentrate. Purify by chromatography (200 mL of flash silica gel; eluant: 7% CH₃OH-CH₂Cl₂). Combine appropriate fractions and concentrate to give 1.72 g (6.09 mmol, 72%) of the title compound as a colorless oil. MS (FAB): m/e 283 (M+1).









Dissolve the product (1.50 g, 5.06 mmol) of Prep. 2A in dry THF (20 mL) and cool to -78°C under N₂. Add [(CH₃)₃Si]₂NLi (5.5 mL of 1.0 M in THF, 5.5 mmol) and stir at -78°C for 1 h. Add bromomethylcyclopropane (0.820 g, 0.59 mL, 6.07 mmol), warm slowly to 23°C and stir for 16 h. Add saturated aqueous NH₄Cl (40 mL), extract with EtOAc (3x30 mL), wash combined organic extracts with saturated aqueous NaCl, dry (MgSO₄), filter and concentrate. Purify by chromatography (175 mL of flash silica gel; eluant: 2% CH₃OH-CH₂Cl₂ then 4% CH₃OH-CH₂Cl₂). Combine appropriate fractions and concentrate to give 0.93 g (2.65 mmol, 53%) of the title compound as a colorless oil. MS (FAB): m/e 351 (M+1)




Treat the product of Prep. 2A in a procedure similar to that described for Prep. 2E, using allyl bromide. MS (CI/CH₄): m/e 337 (M+1).

- 13 -

Step 4: Separately dissolve the products of Prep. 2A to 2F in CH_2Cl_2 , add trifluoroacetic acid and stir at 23°C for 4 h. Concentrate, add 1 N NaOH, extract with CH_2Cl_2 , dry the combined organic extracts (MgSO_4), filter and concentrate to obtain the corresponding substituted piperidines:

Prep.	Substituted Piperidine	Data
2-A		MS(Cl/ CH_4):m/e197(M+1)
2-B		MS(Cl/ CH_4):m/e183(M+1)
2-C		MS(Cl/ CH_4):m/e213(M+1)
2-D		MS(Cl/isobutane): m/e183(M+1)
2-E		MS(Cl/ CH_4):m/e251(M+1)
2-F		MS(Cl/ CH_4):m/e237(M+1)

5

Preparation 3

Step 1: Using the procedures of Preparation 2, substitute 4-amino-1-benzylpiperidine for 4-aminomethyl-1-(1,1-dimethylethoxycarbonyl)-piperidine in Prep. 2, Step 2A and proceed through Prep. 2, Step 3.


- 10 **Step 2:** Treat palladium hydroxide (2.0 g) in EtOAc (100 mL) with the product of Step 1 (25.0 g, 0.0918 mol) in EtOAc (200 mL) and $(\text{tBOC})_2\text{O}$ in EtOAc (200 mL). Shake the resulting mixture on a Parr shaker at 50 psi of H_2 pressure for 3 h then add more palladium hydroxide catalyst (2 g) and shake for 16 h. Filter off catalyst and wash with EtOAc. Concentrate and
- 15 purify by chromatography (silica gel; eluant: 5% $\text{CH}_3\text{OH}-\text{CH}_2\text{Cl}_2$). Combine appropriate fractions and concentrate to give 24.37 g of the product as a white solid. MS (FAB): m/e 283 (M+1).

Step 3: Treat the product of Step 2 according to a procedure similar to that described for Preparation 2F. MS (Cl/ CH_4): m/e 267 (M-55).

- 20 **Step 4A:** Treat the product of Step 3 (5.17 g, 16.0 mmol) in EtOAc (90 mL) and H_2O (90 mL) with NaIO_4 (20.57 g, 96.2 mmol) and RuO_2 (0.064 g,

- 14 -

0.48 mmol). Stir at 23°C for 5 h, add 1 N HCl (20 mL) and filter. Wash solid with EtOAc and H₂O. Separate layers of filtrate and extract with EtOAc. Dry combined organic extracts (MgSO₄), charcoal, and concentrate to give 5.10 g of the title compound. MS (FAB): m/e 341 (M+1).



Step 4B: Treat the product of Preparation 2F according to a procedure similar to that described in Step 4A to give the protected amino acid.











Step 5A: The substituted piperazines 3A5 to 3H5 as well as 3N5 and 3O5 are prepared in a similar procedure using the appropriate amine. Treat the product of Step 4A (1.00 g, 2.94 mmol) in CH₂Cl₂ (20 mL) with carbonyl-diimidazole (0.57 g, 3.53 mmol) and stir at 23°C for 4 h. Add the appropriate amine and stir for 16 h. Add 1 N HCl and extract with CH₂Cl₂. Dry the combined organic extracts (MgSO₄), filter, and concentrate. Purify by chromatography (silica gel; eluant: CH₃OH-CH₂Cl₂). Combine appropriate fractions and concentrate to give 3A5 to 3H5 and 3N5-3O5.

Step 5B: The compounds 3I5 to 3K5 are prepared in a similar procedure to that described in Step 5A substituting the product of Step 4B for the product of Step 4A using the appropriate amine.

Preparation 3L5: Treat the product of Preparation 3, Step 2 according to a procedure similar to that described for Preparation 2F, substituting the product of Example 18L, Step 2, in place of allyl bromide to obtain the title compound.

Prep	Substituted Piperidine	MS
3A5		(FAB) m/e 368 (M+1)
3B5		(CI/CH ₄) m/e 355 (M+1)
3C5		(CI/CH ₄) m/e 284 (M-55)
3D5		(FAB) m/e 410 (M+1)

- 15 -

3E5		(FAB) m/e 394 (M+1)
3F5		(FAB) m/e 396 (M+1)
3G5		(FAB) m/e 384 (M+1)
3H5		(FAB) m/e 424 (M+1)
3I5		(FAB) m/e 398 (M+1)
3J5		(CI/CH4) m/e 354 (M+1)
3K5		(CI/CH4) m/e 424 (M+1)
3L5		(FAB) m/e 370 (M+1)
3N5		(FAB) m/e 423 (M+1)
3O5		(FAB) m/e 426 (M+1)

Step 6: The compounds 3A6 to 3N6 are prepared by treating the products 3A5 to 3O5 (Step 5) according to a procedure similar to Prep. 2, Step 4.




Preparation of 3O6 is carried out by treating the product of Preparation 3, Step 1 according to a procedure similar to that described for Preparation


5 3, Step 2, omitting the (t-BOC)₂O to obtain the title compound.

- 16 -

Preparation	Substituted Piperidine	MS
3A6		(Cl/CH4) m/e 268 (M+1)
3B6		(Cl/CH4) m/e 254 (M+1)
3C6		(FAB) m/e 240 (M+1)
3D6		(Cl/CH4) m/e 310 (M+1)
3E6		(Cl/CH4) m/e 294 (M+1)
3F6		(Cl/CH4) m/e 284 (M+1)
3G6		(Cl/CH4) m/e 296 (M+1)
3H6		(FAB) m/e 324 (M+1)
3I6		(Cl/CH4) m/e 298 (M+1)
3J6		(Cl/CH4) m/e 254 (M+1)
3K6		(Cl/CH4) m/e 324 (M+1)
3L6		


- 17 -

3M6		(FAB) m/e 323 (M+1)
3N6		(FAB) m/e 326 (M+1)
3O6		(FAB) m/e 183 (M+1)

Preparation 4**Preparation 4A**

- 5 Step 1: Treat N-benzyl-piperidone (8.00 g, 0.0423 mol) in CH₂Cl₂ with (CH₃)₃SiCN (4.82 g, 0.0486 mol) and ZnI₂ (0.68 g, 0.0021 mol). Stir at 23 °C for 16 h and concentrate. Add CH₃OH saturated with NH₃ (30 mL) and heat at 40 °C. Concentrate the resulting mixture, add CH₂Cl₂ (200 mL), dry (MgSO₄), filter and concentrate to give 11.06 g of the desired
- 10 product as a yellow oil. MS (CI/CH₄): m/e 189 (M-26).
Step 2: Treat the product of Step 1 according to a procedure similar to that of Preparation 2, Steps 2A and 3. MS (CI/CH₄): m/e 298 (M+1).
Step 3: Treat the product of Step 2 (1.50 g, 5.04 mmol) in t-BuOH (25 mL) with KOH (0.99 g, 17.64 mmol) and reflux for 30 min. Cool to 23 °C and
- 15 concentrate. Add saturated NaCl (40 mL), extract with CH₂Cl₂ (3x40 mL), dry (MgSO₄), filter and concentrate. Purify by flash chromatography (silica gel; eluant: 10% CH₃OH-CH₂Cl₂). Combine appropriate fractions and concentrate to give 0.98 g of the desired product as a yellow solid. M.p. = 184-186 °C. MS (FAB): m/e 298 (M-17).
- 20 Step 4: Treat the product of Step 3 (0.97 g, 3.08 mmol) in CH₃OH (25 mL) with palladium hydroxide (0.40 g). Shake on Parr shaker at 50 psi of H₂ pressure for 16 h. Filter, wash with CH₃OH and concentrate to give 0.69 g of the title compound as a white solid. m.p. = 180-185 °C. MS (FAB): m/e 210 (M-15)


- 18 -

**Preparation 4B**

- Step 1: Treat the product of Prep. 4A, Step 2 (1.50 g, 5.04 mmol) in CH_2Cl_2 (25 mL) with trichloroethyl chloroformate (TROC-Cl) (1.39 g, 6.55 mmol). Stir at 23 °C for 16 h. Add 0.25 N NaOH (40 mL), extract with CH_2Cl_2 (3x40 mL), dry (MgSO_4), filter and concentrate. Purify by flash chromatography (silica gel; eluant: 1:1 EtOAc: hexane to 2:1 EtOAc:hexane). Combine appropriate fractions and concentrate to give 1.31 g of the desired compound as a white solid. m.p. = 185-186 °C. MS (Cl/ CH_4): m/e 382 (M+1).
- Step 2: Treat the product of Step 1 (1.30 g, 3.40 mmol) in THF (20 mL) with HOAc (1.9 mL, 34.0 mmol) and zinc (2.22 g, 34.0 mmol). Stir at 23 °C for 18 h. Add H_2O (10 mL), filter and wash with EtOAc. Add 6.25 N NaOH to filtrate, extract with CH_2Cl_2 , dry (MgSO_4), filter and concentrate to give 0.70 g of the title compound as a white solid. MS (Cl/ CH_4): m/e 208 (M+1).

Preparation 4C

- Step 1: Treat 4-cyano-4-phenylpiperidine in CH_3OH with 50% KOH / H_2O and heat in a sealed tube at 180 °C for 2 h. Cool to 23 °C and concentrate to give the desired compound.
- Step 2: Treat the product of Step 1 with di-t-butyl-dicarbonate according to a procedure similar to that in Preparation 2 Step 1 to give the protected amino acid.
- Step 3: Couple the product of Step 2 with morpholine according to a procedure similar to Example 8 using DMF as a solvent.
- Step 4: Deprotect the amine using a procedure similar to Prep. 2, Step 4, optionally substituting HCl for TFA.

**Preparation 4D**

- Step 1 Cool acetaldehyde (4.6 g, 105 mmol) and dimethylacetone dicarboxylate (7.1 g, 35 mmol) to 0°C and treat with benzylamine (5.2 g, 49 mmol), 12 N HCl, (4.1 mL), and H_2O (3 mL). Stir at 23°C for 16 h. Concentrate the reaction mixture, add acetone (20 mL), filter and concentrate. Add 6 N HCl (30 mL) and heat at 80°C for 16 h. Cool the

- 19 -

resulting solution to 23°C, basify to pH 10 with KOH pellets and extract with CH₂Cl₂ (3x80 mL). Dry combined organic extracts (MgSO₄), filter and concentrate. Purify by flash chromatography (silica gel; eluant: 10% EtOAc-hexane). Combine appropriate fractions and concentrate to give

5 1.8 g of yellow oil. MS (FAB) m/e 218 (M+1).

Step 2: Treat the product of Step 1 (1.7 g, 8.3 mmol) in CH₃OH (10 mL) with H₂NOH•HCl (1.2 g, 16.8 mmol) and CH₃CO₂Na (2.05 g, 25 mmol). Reflux for 4 h then cool to 23°C and concentrate. Add saturated NH₄Cl and extract with CH₂Cl₂. Dry combined organic extracts (Na₂SO₄), filter

10 and concentrate to give 1.6 g of brown oil. MS (FAB) m/e 233 (M+1).


Step 3: Treat the product of Step 2 (1.5 g, 6.46 mmol) in EtOH (20 mL) with Raney nickel (1 g, washed with EtOH). Shake on Parr shaker at 41 psi of H₂ pressure for 16 h. Filter the reaction mixture and concentrate. Purify by flash chromatography (silica gel; eluant: 7% CH₃OH with NH₃-CH₂Cl₂). Combine appropriate fractions and concentrate to give 0.85 g of

15 a clear oil. MS (FAB) m/e 217 (M+1).

Step 4: Proceed in a similar fashion as described for Preparation 306 substituting the product of Step 3 for 4-amino-N-benzylpiperidine. MS (FAB) m/e 211 (M+1).

20

Preparation 5



Step 1: Cool a solution of (*R*)-(+)-4-benzyl-2-oxazolidinone (100 g, 563 mmol) and 1,10-phenanthroline (10 mg) in dry THF (1.25 L) to -78 °C and add *n*-BuLi via addition funnel at a rate such that the internal temperature remains ≤ -70 °C. Add *n*-BuLi (350 mL of 1.6 M in hexane, 350 mmol,

25 1eq) until the reaction turns brown from the phenanthroline complex (ca. 349.5 mL). After 15 min, add 3-carbomethoxypropionyl chloride (69.5 mL, 564 mmol, 1 eq) over 10 min via syringe. Stir the resulting solution for 30 min at -78°C. Allow the mixture to warm to 23°C then pour into EtOAc (2.5

30 L) / sat. NH₄Cl (1 L). Wash the organic layer with saturated NH₄Cl (1 L), saturated NaHCO₃ (2.5 L) and saturated NaCl (2.5 L), then dry (MgSO₄) and concentrate to obtain a yellow solid. Recrystallize the solid from hot isopropanol (820 mL) to give 157.9 g (542 mmol, 96%) of pure product as a colorless crystalline solid, mp 90-92 °C.




- 20 -

- Step 2: Cool a solution of TiCl_4 (419 mL of 1M in CH_2Cl_2 , 419 mmol) in dry CH_2Cl_2 (1.35 L) to 0 °C and treat with $\text{Ti}(\text{O}i\text{-Pr})_4$ (41.4 mL, 140 mmol) via syringe. After 10 min at 0 °C, add diisopropylethyl amine (102.4 mL, 587 mmol) via dry addition funnel. Stir the resulting solution for 15 min at 0 °C then add the product of Step 1 (163.2 g, 561 mmol) in one portion. Stir the solution for 1 h at 0 °C then add freshly distilled acrylonitrile (147 mL, 2.24 mol) via dry addition funnel. Allow the resulting mixture to stand at 4 °C for 18 h then pour the reaction mixture into 25% aq NH_4Cl (4 L) / EtOAc (6 L). Wash the organic layer with 12.5% aq NH_4Cl (2 x 4 L), saturated NaHCO_3 (4 L), and saturated NaCl (4 L) then dry (MgSO_4) and concentrate. Dissolve the crude product in EtOAc and filter through a pad of silica gel (500g). Concentrate the filtrate (6 L) and recrystallize in hot CH_3OH (4 mL/g) to give 116.5 g (338.3 mmol, 60%) of the pure product as a colorless crystalline solid, mp. 103-105 °C.
- Step 3: Treat a solution of the product of Step 2 (25g, 72.6 mmol) in CHCl_3 (100 mL) and CH_3OH (400 mL) with PtO_2 (1.25 g) and place on the Parr shaker @ 45 psi. Shake for 24 h, then filter the mixture through a pad of Celite. Concentrate the filtrate to give 28.3 g of crude amine•HCl.
- Step 4: Treat a solution of the product of Step 3 (72.6 mmol) in 1,2-dichloroethane (500 mL) with HOAc (6 mL, 105 mmol, 1.4 eq) followed by *N*-Boc-4 piperidone (14.6 g, 73.5 mmol, 1.01 eq,) and $\text{NaB}(\text{OAc})_3\text{H}$ (25.7 g, 122 mmol, 1.7 eq). Stir for 1.0 h, then pour the mixture into CH_2Cl_2 (1.4 L). Wash with saturated aqueous NaHCO_3 (2x560 mL), dry (MgSO_4) and concentrate to give 39.1 g of product.
- Step 5: Stir a solution of the product of Step 4 (72.6 mmol) in CH_3CN (500 mL) for 72 h at 50 °C. Cool and concentrate to give 39.3 g of lactam.
- Step 6: Treat a solution of the product of Step 5 (39.3g) (containing up to 72.6 mmol of a mixture of *N*-benzyl and *N*-methyl-cyclohexyl oxazolidinones) in CH_3OH (150 mL), with NaOH (148 mL of 1 N aqueous NaOH, 2.2 eq). Stir for 6 h at 23 °C, then concentrate. Add H_2O (50 mL) and wash with EtOAc (3 x 200 mL) to remove the oxazolidinone. Acidify to pH 2 with 40 mL of 15% aq. HCl (4.4 M) and extract with CH_2Cl_2 (4 x 200 mL). Dry (MgSO_4) the combined extracts and concentrate to give the pure acid as a colorless foam (22.3 g, 65.5 mmol, 96% ee). Recrystallize from hot acetone (18 mL/g, reflux, filter, cool, remove ca. 300 mL solvent on rotovap, seed and sonicate, cool to 10 °C, isolate by filtration with 50 mL cold acetone wash) to give 16.5 g (48.5 mmol) of the pure product as a colorless solid, 16.5 g, (48.5 mmol, 67% from the product of Step 2); m.p.


- 21 -

145-147 °C, >99% ee by chiral HPLC: Daicel Chiracel OD column, 85:15 hexane / isopropanol with 0.1 % TFA).

- Step 7:** Treat a solution of the product of Step 6 (10.0g, 0.029 mol) in CH₂Cl₂ (100 mL) with HOBT (6.0 g, 0.044 mol), the appropriate amine in THF (or dioxane) (0.044 mol), and DCC (9.1 g, 0.044 mol). Stir at 23 °C for 4 h. Filter and wash with 0.5 N NaOH. Separate layers, extract with CH₂Cl₂, dry (MgSO₄), filter and concentrate. Purify by flash chromatography (silica gel, eluant: EtOAc then 5% CH₃OH-EtOAc). Combine appropriate fractions and concentrate to give the product.
- Step 8:** Treat a solution of the product of Step 7 in CH₂Cl₂ (125 mL) with TFA (25 mL). Stir at 23 °C for 4 h and concentrate. Add H₂O (25 mL) and basify with 20 wt % NaOH. Extract with 20% EtOH in CH₂Cl₂ (7x100 mL), dry (MgSO₄), filter, and concentrate to give the products 5A to 5C.

Preparation	Substituted Piperidine	MS
5A		(Cl/CH ₄) m/e 268 (M+1)
5B		(Cl/CH ₄) m/e 254 (M+1)
5C		(FAB) m/e 240 (M-55)

Preparation 6



- Step 1:** Use the procedures of Example 11, Steps 1, 2 and 3, using 3,5-dichlorobenzoyl chloride in place of 3,5-bistrifluorobenzoyl chloride, to obtain the corresponding ketone product.
- Step 2:** Treat the product of Step 1 with H₂NOH HCl using a procedure similar to that described in Example 1 to obtain the title compound. Separation of the Z/E oxime mixture was performed by SiO₂ chromatography, eluting with mixtures of EtOAc:CH₂Cl₂ to obtain the pure Z isomer as a colorless solid.

- 22 -

Method A:

Step 3A: Dissolve the product of Step 2 (134 g) in CH₂Cl₂ (1.5 L). Treat sequentially with HOBT (44.6 g), BOC-D-phenylglycine (86.3 g) and DEC (65.9 g). Stir the mixture at 23 °C for 18 h, heat at reflux temperature for 2 h, recool to 23 °C, treat with saturated NaHCO₃ solution (500 mL), separate the organic portion, dry (MgSO₄), filter and concentrate. Recrystallize the crude material, once from Et₂O and twice from *i*Pr₂O to give 1,1-dimethylethyl-[[[1-[[[(3,5-dichlorobenzoyl)methylamine)methyl]-2-(3,4-dichlorophenyl)-5-methyl-hexen-1-ylidene]amino]oxy]-2-oxo-1-phenylethyl]carbamate (51 g). MS(FAB): m/e 722; [α]_D²³ = -96.9° (c 0.4 CH₂Cl₂) ; m.p. 98 - 102 °C (dec).


Step 4A: Dissolve the product of Step 3A, (25.2 g) in a 0.5M solution of H₂NNH₂ in CH₂Cl₂:CH₃OH (2:1) (200 mL) and stir at 23 °C for 30 min. Dilute the reaction mixture with CH₂Cl₂ (100 mL), wash with H₂O (100 mL), dry (MgSO₄), filter and concentrate. Purify the product by filtration through a pad of silica gel eluting with CH₂Cl₂ to give the title compound (15.6 g). MS(FAB): m/e 647.

Method B:

Step 3B: Dissolve the product of Step 2 (750 g) in CH₂Cl₂ (4.5 L) at 0 °C. Treat sequentially with Et₃N (233 g), DMAP (2.8 g) and pivaloyl chloride (204 g). Stir the mixture at low temperature, adding additional CH₂Cl₂ (4 L) to maintain homogeneity. After 20 min., add H₂O (100 mL), stir for 10 min., wash with saturated NaHCO₃ solution (2 L), H₂O (2 L), dry (Na₂SO₄) and concentrate at 23 °C. Purify the oily product by filtration through a pad of silica gel eluting with CH₂Cl₂ to give 3,5-dichloro-N-[3-(3,4-dichlorophenyl)-2-[[[(2,2-dimethyl-3-oxopropoxy)imino]-6-methyl-5-heptenyl]-N-methylbenzamide (846 g).

Step 4B: The product from Step 3B is resolved using a Chiralpak ADTM column, eluting with mixtures of hexane/*i*PrOH.

Step 5B: Treat the desired enantiomer from Step 4B according to a procedure similar to Method A-Step 4A to afford the title compound.

Preparation 7

- 23 -

Step 1: Treat a solution of 3,4-dichlorophenylacetic acid (25 g) with N-t-BOC-sarcosine methyl ester (24.3 g) (prepared from sarcosine methyl ester HCl and di-t-butyldicarbonate) according to a procedure similar to Example 11, Step 2, to give the desired product (36 g).


5 Step 2: Treat 2-bromoethanol (107 g) in CH₂Cl₂ (2 L) at 0 °C with t-butyldimethylsilylchloride (143 g), NEt₃ (130 g) and DMAP (11 g), allow the reaction mixture to warm to 23 °C and stir for 18 h. Wash the mixture with H₂O (250 mL), 20% HCl (250 mL), 20% NH₄OH (250 mL), dry (MgSO₄) and concentrate to give 2-(t-butyldimethylsilyloxy)-ethylbromide (197 g).

10 Step 3: Treat the product of Step 1 (57 g) in DMF (500 mL) at -10 °C with NaH (8.6 g, 60% disp. in oil) and stir for 1 h. Add 2-(t-butyldimethylsilyloxy)ethylbromide (51.3 g) and NaI (6.4 g) and stir for 18 h. Add EtOAc (400 mL) and saturated NaCl solution (300 mL). Separate the organic portion, dry (MgSO₄), filter and concentrate. Purify the crude oil by silica gel chromatography eluting with EtOAc/hexane mixtures to give product (60.1 g).

15 Step 4: Treat the product from Step 3 (28 g) with O-allylhydroxylamine HCl (17 g) according to a procedure similar to Example 1, to give the title compound (24.5 g).

Example 1

1-[[[(3,5-bis(trifluoromethyl)phenyl)methoxy]-3-(3,4-dichlorophenyl)-5-(4-hydroxy-4-phenyl-1-piperidiny)]-2-pentanone O-methyloxime]




25 Treat a solution of the product of Preparation 1 (270 mg, 0.417 mmol) in dry pyridine (5 mL) with O-methoxylamine HCl (52 mg, 0.626 mmol, 1.5 eq) and heat to 60°C for 30 min. Allow the vessel to cool to 23°C and remove the pyridine *in vacuo*. Take up the crude product in a minimal amount of CH₂Cl₂ (2 mL) and apply to a silica gel column (2.5 cm x 15 cm) packed with hexane:EtOAc:triethylamine (66:33:1). Elute with the same solvent system to obtain 190 mg (0.281 mmol, 67%) of the title compound as a colorless foam.

30 HRMS (FAB, M+H⁺): *m/e* calc'd for [C₃₂H₃₃N₂O₃Cl₂F₆]⁺: 677.1772, found 677.1785.


- 24 -

Example 1A (Z isomer) is prepared from the product of Preparation 1 in a procedure similar to that described for Example 1, using hydroxyl amine HCl as the starting material:




5 HRMS (FAB, $M+H^+$): calc'd: 663.1616, found 663.1625.

Example 2



10 Treat a solution of Example 1A (400 mg, 0.603 mmol) in dry DMF (12 mL) at 0 °C with 60% NaH in mineral oil (48 mg), stir for 40 min and treat with methyl bromoacetate (60 μ L, 0.633 mmol, 1.05 eq). Stir for 30 min, pour into EtOAc (250 mL) / half saturated NaHCO_3 (200 mL) and extract. Wash the organic layer with water (2x100 mL), then brine (10 mL) and dry over Na_2SO_4 . Purify the crude mixture by silica gel chromatography (4 x 15 cm; hex/EtOAc 1:1 w/ 2% NEt_3) to give 361.8 mg
15 (0.492 mmol, 82%) of the pure product as an oil. HRMS (FAB, $M+H^+$): m/e calc'd for $[\text{C}_{34}\text{H}_{34}\text{Cl}_2\text{F}_6\text{N}_2\text{O}_5]^+$: 735.1827, found 735.1839.


Using a similar procedure, treat the product of Example 1A with the appropriate alkyl halide to obtain the following compounds 2A-2C:




Ex.	R ¹	Alkyl Halide	HRMS calc'd (FAB, $M+H^+$)	HRMS Found
2A	$-\text{CH}_2\text{CN}$	Br-acetonitrile	702.1725	702.1720
2B	$-\text{CH}_2\text{CH}_2\text{OH}$	2-Br-1-(t-Bu-dimethylsilyloxy)-ethane*	707.1878	707.1856
2C	$-(\text{CH}_2)_3\text{-phthalyl}$	N-(3-Br-propyl)-phthalimide	850.2249	850.2248

20 * Followed by desilylation with 1M TBAF in THF (3 h, 23°C).

- 25 -

Example 3


Treat a solution of the product of Example 2 (57 mg, 0.078 mmol) in MeOH (3 mL) at 0 °C with gaseous ammonia for 5 min. After venting 2-3 times, seal the vessel with a polypropylene cap and stir until TLC shows the reaction is complete (20 h) to give (56 mg, 0.078 mmol, >99%) of the pure product as a colorless powder. HRMS (FAB, $M+H^+$): m/e calc'd for $[C_{33}H_{33}Cl_2F_6N_3O_4]^+$: 720.1831, found 720.1841.

Example 4

10

Treat a suspension of $H_2NOH \cdot HCl$ (47 mg, 0.68 mmol, 5 eq) in ethanol with KOH in MeOH (680 μ L, 0.68 mmol, 5 eq), sonicate for 5 min and then add to a solution of Example 2A (95 mg, 0.135 mmol) in ethanol (5 mL). Heat for 2.5 h at 60 °C, filter, concentrate in vacuo and purify by silica gel chromatography (2.5 x 14 cm; $CH_2Cl_2/MeOH (NH_3)$ 95:5) to give 98.3 mg (0.134 mmol, 99%) of the product as a film. HRMS (FAB): 735.1956 ($M+H^+$).


15

Examples 5, 5A and 5B

20

Using the procedures described below, compounds of the structural formula above were prepared, wherein the definitions of R^1 are shown in the following table:

- 26 -

Ex.	R ¹	HRMS calc'd (FAB, M+H ⁺)	HRMS Found
5	-CH ₂ CN	634.1198	634.1206
5A	-CH ₂ CH ₂ OH	639.1351	639.1342
5B		667.1351	639.1342

Example 5:

Step 1: Prepare the allyl oxime ether of the product of Example 6, Step 7, employing *O*-allylhydroxylamine HCl as the alkoxyl amine.

Step 2: Remove the silyl protective group in a procedure similar to that described in Example 6, Step 8.


Step 3: Alkylate the hydroxyl group with 3,5-dichlorobenzylbromide in a procedure similar to that in Example 6, Step 9.

Step 4: Treat a solution of the product of step 3 (285 mg, 0.426 mmol) in 80% aqueous EtOH with Pd(PPh₃)₄ (25 mg, 0.021 mmol, 0.05 eq) and triethylammoniumformate (2.13 mL of 1M solution in THF, 5 eq) and stir at reflux for 4 h. Cool, concentrate and purify by silica gel chromatography (2.5 x 16.5 cm; hex/EtOAc 1:1 w/ 2% NEt₃) to give 185 mg (0.3095 mmol, 73%) as a film.

Step 5: Treat the product of step 4 in a similar fashion to Example 2, using BrCH₂CN as the alkyl halide.

Example 5A: Treat the product of Example 5, step 4, in a similar fashion to Example 2, using 2-bromo-1-(*t* butyldimethylsiloxy)ethane as the alkyl halide, followed by desilylation (3 h, 23°C) with 1M TBAF in THF.

Example 5B: Treat the product of Example 5, Step 5, in a similar fashion to Example 4 to obtain the desired product.

Example 6

Steps 1-6: Prepare 3-(3,4-dichlorophenyl)-1-[[dimethyl(1,1-dimethylethyl)silyl]oxy]-5-(4-hydroxy-4-phenyl-1-piperidinyl)-2-pentanone as described in U.S. 5,696,267.


Step 7: Treat a solution of the product of Step 6 (6.6 g, 12.3 mmol) and NaOAc (6.05 g, 73.8 mmol) in EtOH (110 mL) and H₂O (27 mL) with

- 27 -

NH₂OCH₃•HCl. Stir the resulting solution for 12-18 hours at room temperature. Concentrate under reduced pressure and partition the resulting residue between CH₂Cl₂ (100 mL) and H₂O (100 mL). Extract the aqueous layer with CH₂Cl₂ (3 x 100 mL), dry the combined organic
5 layers over MgSO₄, filter and concentrate under reduced pressure to yield the crude product as a pale oil. This product is carried on without purification to the next step. HRMS (FAB, M+H⁺): *m/e* cal'd for [C₂₉H₄₃N₂O₃SiCl₂]⁺: 565.2420, found 565.2410.

Step 8: Treat a solution of the crude oxime from Step 7 (≤ 12.3
10 mmol) in THF (400 mL) with TBAF (15.4 mL, 15.4 mmol, 1M in THF) at 0°C. Stir the solution for 2 hours. Quench the reaction with water and extract the aqueous phase with EtOAc (3 x 100 mL). Dry the combined organic layers over MgSO₄, filter and concentrate under reduced pressure to give the crude product as a yellow oil. Purify by silica gel chromatography
15 (column: 7.5 cm x 20 cm; pack column in CH₂Cl₂ and elute using a gradient of 100% CH₂Cl₂ to 5% CH₃OH(NH₃)/CH₂Cl₂) to obtain 16 g (29.9 mmol, 75% from Step 6) of the desired compound as a white solid. HRMS (FAB, M+H⁺): *m/e* cal'd for [C₂₃H₂₉N₂O₃Cl₂]⁺: 451.1555, found 451.1553.

Step 9: Treat a solution of the product of Step 8 (200 mg, 0.44 mmol) in DMF at 0°C with NaH (12 mg, 0.48mmol). Stir the resulting mixture for 30 mins at 0°C. Add 2,4-difluorobenzylbromide (60 μL, 0.465 mmol) in one portion and remove cooling bath. Stir the reaction for 12-18 hours at room temperature. Quench the reaction with H₂O and extract with EtOAc
25 (3 x 30 mL). Dry the combined organic layers over MgSO₄, filter and concentrate under reduced pressure to give the crude compound as a yellow oil. Purify by silica gel chromatography (column: 2.5 cm x 15 cm; pack column in 50% EtOAc/Hexane and elute using a gradient of 50-100% EtOAc/Hexane) to obtain 128mg (0.22 mmol, 50%) of the title
30 compound as a pale oil. HRMS (FAB, M+H⁺): *m/e* cal'd for [C₃₀H₃₃N₂O₃Cl₂F₂]⁺: 577.1836, found 577.1832.

Example 7

- 28 -

Step 1: Add the product of Example 6, Step 8 (1.8 g) and TFA (0.31 μ L) to *o*-iodoxybenzoic acid (2.24 g) in DMSO (20 mL). Stir the mixture for 2 h and add ice/H₂O (50 mL), conc. NH₄OH soln. (5 mL) and EtOAc (50 mL).

- 5 Stir the mixture and filter to remove solids. Wash the solid residue with H₂O (2X20 mL) and EtOAc (2X20 mL). Combine the filtrates, separate the organic layer and wash with H₂O (2X25 mL), dry over MgSO₄, filter and evaporate to give 3-(3,4-dichlorophenyl)-5-(4-hydroxy-4-phenyl-1-piperidiny)-2-(2-methoxyimino)pentanal (1.8 g) as a foamy solid.

Mass spectrum (FAB): 449.


- 10 Step 2: Treat the product of Step 1 (0.2 g) in CF₃CH₂OH (5 mL) with 3Å molecular sieves (1.0 g) and 3,5-bistrifluoromethylbenzylamine (0.14 g). Stir the mixture for 90 min. and add NaBH₃CN (0.12 g). After 18 h. filter the reaction mixture through a pad of Celite, rinse the Celite with MeOH (10 mL) and evaporate the combined filtrates. Partition the residue
15 between CH₂Cl₂ (15 mL) and 20% KOH (15 mL). Separate the organic layer and extract the aqueous layer with CH₂Cl₂ (2X20 mL). Combine the organic extracts, dry over MgSO₄, filter and evaporate to give a solid. Purify the crude by silica gel chromatography eluting with NH₃/MeOH/CH₂Cl₂ mixtures to give the title compound (0.1 g). HRMS (FAB, M+H⁺):
20 m/e calc'd for [C₃₂H₃₄N₃O₆Cl₂F₆]⁺: 676.1932, found 676,1940.

Example 7A:

3-(3,4-Dichlorophenyl)-5-(4-hydroxy-4-phenyl-1-piperidiny)-1-[[[(2-methoxyphenyl)methyl]amino]-2-pentanone O-methyloxime.

- 25 Using the product of Example 7, Step 1 as starting material, prepare the compound of Example 7A using 2-methoxybenzylamine in a procedure similar to that described in Example 7, Step 2. HRMS (FAB, M+H⁺): m/e calc'd for [C₃₁H₃₇N₃O₃Cl₂]⁺: 570.2290, found 570.2291

Example 8




- 30 Treat the product of Example 7A (50 mg) in CH₂Cl₂ (5 mL) with HOBT (12.4 mg) and AcOH (1 mL) and cool to 0°C. To the cold solution, add DEC (17.6 mg) and stir for a further 18 h. Wash the reaction mixture with 10% NH₄OH soln. (3 mL). Reextract the aqueous layer with

- 29 -

CH₂Cl₂ (3X3 mL), combine the organic portions, dry over MgSO₄, filter and evaporate to give a solid. Purify the crude by silica gel chromatography eluting with NH₃/MeOH/CH₂Cl₂ mixtures to give the title compound (0.042 g).

- 5 Analysis: Calc'd for C₃₃H₃₉N₃O₄Cl₂ · 0.5H₂O; C, 63.76, H, 6.49, N, 6.76. Found: C, 63.83, H, 6.85, N, 6.95.

Example 9



- 10 Step 1-7: Prepare 1-[[3,5-bis(trifluoromethyl)phenyl]methoxy]-3-(3,4-dichlorophenyl)-5-hydroxy-2-pentanone O-methyloxime as described in U.S. 5,696,267.

Step 8:


- 15 Dissolve oxalyl chloride (2.01 g, 15.82 mmol) in dry CH₂Cl₂ (30 mL) and cool to -78°C under N₂, add DMSO (2.47 g, 31.64 mmol) in dry CH₂Cl₂ (12 mL) dropwise and stir at -78°C for 15 mins. Add the product of Step 7 (6.56 g, 12.66 mmol) in dry CH₂Cl₂ (20 mL) dropwise and stir at -78°C for 3 h. Add diisopropylethylamine (4.91 g, 37.97 mmol) and stir at -78°C for 1 h. Warm slowly to 0°C and stir at 0°C for 30 mins. Add water (150 mL) and extract with CH₂Cl₂. Wash combined organic extracts with saturated aqueous NaCl, dry (MgSO₄), filter, and concentrate to give 6.53 g (12.66 mmol, 100%) of a yellow oil. MS (FAB): m/e 516 (M+1).

Step 9:

- 25 Dissolve the product (1.05 g, 2.03 mmol) of Step 8 and 4-phenylamino-piperidine (1.08 g, 6.13 mmol) in CF₃CH₂OH (10 mL), add crushed 3A sieves (1 g) and NaBH₃CN (0.26 g, 4.07 mmol), and stir at 23°C for 4 h. Concentrate and add water (60 mL) and EtOAc (60 mL). Filter through Celite, separate layers of filtrate and extract aqueous solution with EtOAc. Dry combined organic extracts (MgSO₄), filter and concentrate. Purify by chromatography (200 mL of flash silica gel; eluant:3% CH₃OH-CH₂Cl₂). Combine appropriate fractions and concentrate to give 0.98 g (1.45 mmol, 66%) of the title compound as a yellow oil. MS (FAB): m/e 676 (M+1)


- 30 -

The following compound of formula 9A is prepared by reacting the product of Example 9, Step 8, with an appropriate amine according to the procedure of Example 9, Step 9:





5

MS(FAB): m/e 657 (M+1)

Example 10


- Dissolve the product (0.380 g, 0.578 mmol) of Example 9A in
- 10 THF (3 mL) and CH₃OH (1 mL). Add 1 N KOH (2.7 mL, 2.70 mmol) and reflux for 16 h. Cool to 23°C and add 1 N HCl (5 mL) and water (20 mL). Extract with CH₂Cl₂ (3x20 mL), wash combined organic extracts with saturated aqueous NaCl, dry (MgSO₄), filter and concentrate to give 0.312 g (0.496 mmol, 86%) of the title compound as a yellow foam.
- 15 MS (FAB): m/e 629 (M+1)

Example 11


- Treat a suspension of sarcosine methyl ester hydrochloride (6.02 g, 43 mmole) in CH₂Cl₂ (250 ml) at 0°C with 3,5 - bistrifluoromethyl benzoyl chloride (7.7 ml, 42.5 mmole) and Et₃N (12.5 ml, 89.7 mmole). Stir the mixture at 20°C for 1h. Add water (150 ml) to the mixture and separate the
- 20

- 31 -


organic layer. Dry (MgSO_4) and concentrate the organic layer to give crude product. Purify by silica gel chromatography (eluant: EtOAc:hexane (6:4)) to obtain the product 12 g (81%).



- 5 Treat a solution of 3,4-dichlorophenyl acetic acid (4.15 g, 20 mmole) in anhydrous THF (50 ml) at -60°C with $[(\text{CH}_3)_3\text{Si}]_2\text{NLi}$ (46.2 ml, 46.2 mmole) and slowly warm the mixture to 0°C for 4h. Transfer this solution to a solution of the product of Step 1 (5.46 g, 16 mmole) in anhydrous THF (8 ml) at -30°C . Warm the reaction to -10°C over 1 h, stir
- 10 at 0°C for 1 h and at 20°C for 4h. Add 50% of aqueous HOAc (15 ml) and extract with EtOAc. Separate the organic layer, dry (MgSO_4) and concentrate to give the crude product. Purify by silical gel chromatography (eluant: hexane/EtOAc, 6:4) to give 5.21 g (69%) of the product. HRMS (FAB, $\text{M}+\text{H}^+$) = m/e calc'd for $[\text{C}_{19}\text{H}_{14}\text{NO}_2\text{Cl}_2\text{F}_6]^+ =$
- 15 472.0306, found 472.0306




- Treat a solution of the product of Step 2 (0.96 g, 2 mmole) in THF (6 ml) at -78°C with $[(\text{CH}_3)_3\text{Si}]_2\text{NLi}$ (2.5 ml, 2.5 mmole) and stir at -78°C for 25 h. Add a solution of 1-bromo-3-methyl-2-butene (0.42 g) in THF (1 ml)
- 20 to the above anion solution at -78°C , slowly warm the solution to 0°C and stir at 20°C for 2 h. Add saturated NH_4Cl solution (5 ml), extract with EtOAc twice wash the combined EtOAc extracts with brine, dry (MgSO_4) and concentrate to give a crude product. Purify by column chromatography (silica gel; eluant: EtOAc:hexane, 2:8) to obtain 1 g of
- 25 product (87%). MS (FAB, $\text{M}+\text{H}^+$) m/e 540.



- 32 -


- Treat a solution of the product of Step 3 (0.22 g, 0.4 mmole) in pyridine (3 ml) at 70°C with methoxylamine HCl (95 mg, 1.14 mmole), stir at 70°C for 6.5 h and then cool to 20°C. Add water to the reaction mixture, extract the solution with EtOAc, dry (MgSO₄) and concentrate the EtOAc extracts to give the crude product. Purify by silica gel chromatography (eluant: hexane:Et₂O, 1:1) to give 74 mg (32%) of Z-isomer and 130 mg (56%) of E-isomer oximes. MS (FAB, M+H⁺) = m/e 569.

Step 5A:



- Treat the product of Step 4 (0.387 of E-isomer, 0.68 mmole) in a solution of EtOAc saturated with O₃ at -78°C for 5 min. Purge the solution with N₂, add (CH₃)₂S and warm the solution from -78°C to 20°C over 1 h. Concentrate the solution to give the desired aldehyde which is used directly in the next reaction without further purification. MS (FAB.M + H⁺) = m/e 543.

Step 5B:




15

The Z isomer is prepared using a procedure similar to that described in Step 5A employing the Z isomer product of Step 4.

- Step 6: Treat the product of Step 5 with 4-hydroxy-4-phenylpiperidine in a procedure similar to that described in Example 9, Step 9, to obtain the title compound (Z isomer) in overall 77% yield. HRMS(FAB,M+H⁺) = m/e calc'd for [C₃₃H₃₄N₃O₃Cl₂F₆]⁺:704.1881, found 704.1875.

Example 12




- Step 1: Using the procedures of Example 11, substitute 3,5-dichlorobenzoyl chloride in place of 3,5-bis(trifluoromethyl)benzoyl chloride in Step 1 and

25

- 33 -

proceed through Steps 2, 3, 4 and 5, to obtain the title compound. Alternatively, to prepare optically active material, treat the product of Preparation 6 according to a procedure outlined in Example 13, Step 1.









- Step 2: The following compounds of formula 12A to 12S are prepared by reacting the product of Step 1 with an appropriate amine (described in Preparations 3 and 4) according to a procedure similar to Example 9, Step 9. Stereoisomers are separated by HPLC on a chiral column using mixtures of hexane and isopropanol with 0.25% Et₂NH added on a Daicel AD and/or OD column.









10


Example	Z	MS (FAB): m/e
12A		758 (M+1)
12B		714 (M+1)
12C		784 (M+1)
12D		717 (M+1)

- 34 -

12E		756 (M+1)
12F		755 (M+1)
12G		668 (M+1)
12H		668 (M-17)
12I		742 (M+1)
12J		744 (M+1)
12K		770 (M+1)
12L		784 (M+1)


- 35 -

12M		728 (M+1)
12N		636 (M+1)
12O		733 (M+1)
12P		783 (M+1)
12Q		786 (M+1)
12R		669 (M+1)


Example 13

- Step 1: Treat the product of Preparation 6 with CH₃I using the procedure of Example 2, followed by a procedure similar to Example 11, Step 5, to obtain the title compound.
- Step 2: Prepare the following compounds by reacting the product of Step 1 with an appropriate amine (for 13A to 13C see Preparation 5A-5C, for 13D see Preparation 3O6, for 13F treat the product of Preparation 5, Step 5, using a procedure similar to that described in Preparation 2, Step 4 to give the appropriate amino ester) according to a procedure similar to Example 9, Step 9, substituting NaB(OAc)₃H in place of NaBH₃CN and 1,2-dichloroethane for trifluoroethanol. Prepare 13G by treatment of Example 13D with MCPBA in CH₂Cl₂ at 0°C for 3 h; 13H is similarly prepared by treatment of 13B. Example 13E is prepared from Example 13F using standard saponification conditions similar to those described in Preparation 5, Step 6.



- 36 -



Ex.	Z	HRMS Found (FAB, M+H ⁺)	Additional Data
13A		726.2145	$[\alpha]_D^{26} = -41.1^\circ$ (c = 0.6, CH ₂ Cl ₂)
13B		712.1979	$[\alpha]_D^{26} = -42.1^\circ$ (c = 0.6, CH ₂ Cl ₂)
13C		698.1829	$[\alpha]_D^{26} = -42.2^\circ$ (c = 0.6, CH ₂ Cl ₂)
13D		641.1622	$[\alpha]_D^{26} = -52.7^\circ$ (c = 0.28, EtOH)
13E		699.1666	--
13F		713.1831	--
13G		-	MS = 659 (M+1)
13H		-	MS = 730 (M+1)

Example 14

- 37 -

Example	R1	MS (FAB): m/e
14A	CH ₂ CH=CH ₂	754 (M+1)
14B	H	714 (M+1)
14C	CH ₂ CN	753 (M+1)
14D		786 (M+1)
14E		800 (M+1)

Example 14A: Treat the product of Preparation 7 according to a procedure similar to that described in Example 6, Step 8. Proceed in a similar manner as described in Example 9, Steps 8-9, using the product of Preparation 5A or 3A6 in place of 4-phenylamino-piperidine. Proceed in a manner similar to that of Preparation 2, Step 4, optionally substituting HCl for TFA. Acylate the amine according to a procedure similar to Preparation 2, Step 2A, using 3,5 dichlorobenzoyl chloride.


Example 14B: Treat the product of Example 14A using a procedure similar to Example 5, Step 4, to obtain the oxime. Alternatively, for the preparation of optically active material, treat the product of Preparation 6 according to a procedure outlined in Example 11, Step 5B, followed by the procedure of Example 13A, Step 2.

Example 14C : Treat the product of Example 14B with BrCH₂CN according to a procedure similar to Example 2A to give the title compound.








Example 14D: Use a procedure similar to that described in Example 4 using the product of Example 14C to obtain the title compound. The stereoisomers are separated by HPLC on a chiral column using mixtures of hexane and isopropanol with 0.25% Et₂NH added on a Daicel AD and/or OD column.

Example 14E: Treat the product of Example 14C according to a procedure similar to that of Example 18M to obtain the title compound..

Example 15



- 38 -

Example	R1	MS (FAB): m/e
15A	H	700 (M+1)
15B	CH ₂ CN	739 (M+1)
15C	CH ₂ CH ₂ OH	744 (M+1)
15D		757 (M+1)
15E		771 (M+1)
15F		772 (M+1)
15G		841 (M+1)
15H	CH ₂ CH ₂ CH ₂ SO ₃ H	822 (M+1)
15I		796 (M+1)
15J		851 (M+1)
15K	CH ₂ F	732 (M+1)
15L	CH ₂ CH ₃	728 (M+1)
15M		786 (M+1)

Example 15A

Step 1: Treat the product of Preparation 7 using a procedure similar to that described in Example 6, Step 8. Proceed in a similar manner as described in Example 9, Steps 8-9, using the product of Preparation 5B or 3B6 in place of 4-phenylamino-piperidine. Proceed in a manner similar to the procedure outlined in Preparation 2, Step 4, optionally substituting HCl for TFA. Acylate the amine according to a procedure similar to Preparation 2, Step 2A, using 3,5 dichlorobenzoyl chloride.

Step 2: Treat the resultant product using a procedure similar to Example 5, Step 4, to obtain the title compound.

Alternatively, for the preparation of optically active material, treat the product of Preparation 6 according to a procedure outlined in Example 11, Step 5, followed by the procedure of Example 13B, Step 2.

Example 15B: Treat the product of Step 2 with BrCH₂CN according to a procedure similar to Example 2A to give the title compound.

Example 15C: Alkylate and deprotect the product of Example 15A according to a procedure similar to Example 2B to give the title compound.

Example 15D:

5 Step 1: Alkylate the product in Example 15A with allylchloroacetate according to a procedure similar to Example 2 to give the resulting allyl ester.

Step 2: Treat a solution of the product of Step 1 according to a procedure similar to that of Example 3 to give the title compound.

10 **Example 15E:** Treat a solution of Example 15D, Step 1, with CH_3NH_2 according to a procedure similar to that of Example 3 to give the title compound.

15 **Example 15F:** Use a procedure similar to that described in Example 4 using the product of Example 15B to obtain the title compound. The stereoisomers are separated by HPLC on a chiral column using mixtures of hexane and isopropanol with 0.25% diethylamine added on a Daicel AD and/or OD column.

Example 15G:

Step 1: Deprotect the product of Example 15D, Step 1, using a procedure similar to Example 5, Step 4.

20 Step 2: Treat a solution of the product of Step 1 (82 mg) in dry CH_2Cl_2 (1 mL) with NEt_3 (41 μL), followed by BOP-Cl (36.5 mg). Stir 15 min at 23 °C, then add 2-amino-1,3,4-thiadiazole (14 mg). Stir for 2 h, dilute with EtOAc (75 mL) and wash with 10% citric acid followed by H_2O , and then by saturated NaHCO_3 . Dry the organic layers (Na_2SO_4), filter,
25 concentrate and purify by silica gel chromatography to give the title compound.

Example 15H: Alkylate the product of Example 15A using a procedure similar to that described in Example 2 using 1,3-propane sultone in place of methyl bromoacetate to obtain the title compound.

30 **Example 15I:** Couple the product of Example 15G, Step 1, with $\text{H}_2\text{NCH}_2\text{CN}$ using a procedure similar to that in Example 8 to give the title compound.


Example 15J: Couple the product of Example 15G, Step 1, with $\text{H}_2\text{NCH}_2\text{SO}_3\text{H}$ using a procedure similar to that in Example 8 to give the
35 title compound.








Example 15K: Alkylate the product of Example 15A using a procedure similar to that described in Example 2 using BrCH_2F in place of methyl bromoacetate to obtain the title compound.

Example 15L: Treat the product of Example 15A with iodoethane according to a procedure similar to Example 2 to give the title compound.

Example 15M: Treat the product of Example 15B according to a procedure similar to that of Example 18M to obtain the title compound.

Example 16



Example	R1	Physical Data
16A	H	MS = 687 (M+1)
16B	CH ₂ CN	--
16C	CH ₂ CH ₂ OH	--
16D		--
16E		--
16F		--
16G		--
16H	CH ₂ CH ₂ CH ₂ SO ₃ H	--
16I		--
16J		--
16K	CH ₂ F	--
16L	CH ₂ CH ₃	--
16M		--

Example 16A:

Step 1: Treat the product of Preparation 7 using a procedure similar to that described in Example 6, Step 8. Proceed in a similar manner as

described in Example 9, Steps 8-9, using the product of Preparation 5C or 3C6 in place of 4-phenylamino-piperidine. Proceed in a manner similar to

- 41 -

the procedure outlined in Preparation 2, Step 4, optionally substituting HCl for TFA. Acylate the amine according to a procedure similar to Preparation 2, Step 2A, using 3,5 dichlorobenzoyl chloride.

5 Step 2: Treat the resultant product using a procedure similar to Example 5, Step 4, to obtain the title compound.

Alternatively, for the preparation of optically active material, treat the product of Preparation 6 according to a procedure outlined in Example 11, Step 5, followed by the procedure of Example 13C, Step 2.

10 **Example 16B:** Treat the product of Step 2 with the BrCH_2CN according to a procedure similar to Example 2A to give the title compound.

Example 16C: Alkylate and deprotect the product of Example 16A according to a procedure similar to Example 2B to give the title compound.

Example 16D:

15 Step 1: Alkylate the product in Example 16A with allylchloroacetate according to a procedure similar to Example 2 to give the resulting allyl ester.

Step 2: Treat a solution of the product of Step 2 according to a procedure similar to that of Example 3 to give the title compound.

20 **Example 16E** Treat a solution of Example 16D, Step 1, with CH_3NH_2 according to a procedure similar to that of Example 3 to give the title compound.

Example 16F: Use a procedure similar to that described in Example 4 using the product of Example 16B to obtain the title compound. The
25 stereoisomers are separated by HPLC on a chiral column using mixtures of hexane and isopropanol with 0.25% Et_2N added on a Daicel AD and/or OD column.

Example 16G:

30 Step 1: Deprotect the product of Example 16D, Step 1, using a procedure similar to Example 5, Step 4.

Step 2: Treat the product of Step 1 according to a procedure similar to Example 15G, Step 2, to give the title compound.

35 **Example 16H:** Alkylate the product of Example 16A using a procedure similar to that described in Example 2 using 1,3-propane sultone in place of methyl bromoacetate to obtain the title compound.

Example 16I: Couple the product of Example 16G, Step 1, with $\text{H}_2\text{NCH}_2\text{CN}$ using a procedure similar to that in Example 8 to give the title compound.

- 42 -


Example 16J: Couple the product of Example 16G, Step 1, with $\text{H}_2\text{NCH}_2\text{SO}_3\text{H}$ using a procedure similar to that in Example 8 to give the title compound.

Example 16K: Alkylate the product of Example 16A using a procedure similar to that described in Example 2 using BrCH_2F in place of methyl bromoacetate to obtain the title compound.

Example 16L: Treat the product of Example 16A, Step 2 with $\text{CH}_3\text{CH}_2\text{I}$ according to a procedure similar to Example 2 to give the title compound.






Example 16M: Treat the product of Example 16B according to a procedure similar to Example 18M to obtain the title compound.

Example 17



Example	R1	HRMS calc'd (FAB, M+H ⁺)	HRMS Found
17A	H	627.1463	627.1457
17B	CH ₃	641.1620	641.1622
17C	CH ₂ CH ₂ OH	671.1725	671.1733
17D	CH ₂ CN	666.1572	666.1591
17E		699.1787	699.1778
17F		684.1678	684.1639
17G		712.1991	712.1979
17H		698.1834	698.1829
17I		768.1460	768.1466
17J	CH ₂ CH ₂ CH ₂ OH	685.1882	685.1882
17K	CH ₂ CH ₂ CH ₂ SO ₃ ⁻ NH ₄ ⁺	749.1501	749.1508
17L		700.1627	700.1618
17M		741.2256	741.2263
17N		747.1708	747.1716

- 43 -

17O		733.1552	733.1553
17P		731.1759	731.1754
17Q		714.1784	714.1795
17R		728.1940	728.1953
17S	CH ₂ F	659.1526	659.1520
17T			

Example 17A:

Step 1: Treat the product of Preparation 7 using a procedure similar to that described in Example 6, Step 8. Proceed in a similar manner as described in Example 9, Steps 8-9, using the product of Preparation 3O6 in place of 4-phenylamino-piperidine. Proceed in a manner similar to the procedure outlined in Preparation 2, Step 4, optionally substituting HCl for TFA. Acylate the amine according to a procedure similar to Preparation 2, Step 2A, using 3,5 dichlorobenzoyl chloride.

Step 2: Treat the resultant product using a procedure similar to Example 5, Step 4, to obtain the title compound.

Alternatively, for the preparation of optically active material, treat the product of Preparation 6 according to a procedure outlined in Example 11, Step 5, followed by the procedure of Example 13D, Step 2.

Example 17B: Alkylate Example 17A with CH₃I according to a procedure similar to Example 2 to give the title compound.

Example 17C: Alkylate and deprotect the product of Example 17A according to a procedure similar to Example 2B to give the title compound.

Example 17D: Alkylate Example 17A with BrCH₂CN according to a procedure similar to Example 2A to give the title compound.

Example 17E: Use a procedure similar to that described in Example 4, using the product of 17D to obtain the title compound.

Example 17F:

Step 1: Alkylate Example 17A with allylchloroacetate according to a procedure similar to Example 2 to give the resulting allyl ester.

Step 2: Treat a solution of the product of Step 1 according to a procedure similar to that of Example 3 to give the title compound.

- 44 -

Example 17G: Treat a solution of Example 17F, Step 1, with $(\text{CH}_3)_2\text{NH}$ according to a procedure similar to that of Example 3 to give the title compound.

5 **Example 17H:** Treat a solution of Example 17F, Step 1, with CH_3NH_2 according to a procedure similar to that of Example 3 to give the title compound.

Example 17I:

Step 1: Deprotect the product of Example 17F, Step 1, using a procedure similar to Example 5, Step 4.

10 Step 2: Treat the product of Step 1 according to a procedure similar to Example 15G, Step 2, to give the title compound.

Example 17J: Alkylate Example 17A with 3-bromo-1-t-butyltrimethylsilyloxy propane and deprotect using a procedure similar to that described in Example 2B to obtain the title compound.

15 **Example 17K:** Alkylate Example 17A using a procedure similar to that described in Example 2 using 1,3-propane sultone in place of methyl bromoacetate to obtain the title compound.

Example 17L:

20 Step 1: Alkylate the product of Example 17A with methyl bromoacetate using a procedure similar to that described in Example 2 to obtain the methyl ester.

Step 2: Treat the product of Step 1 according to a procedure similar to that in Example 4 to give the title compound.

Example 17M:

25 Step 1: Alkylate the product of Example 17A with bromopropylphthalimide using a procedure similar to that described in Example 2C to obtain the protected propylamine.

Step 2: Treat the product of Step 1 with $(\text{CH}_3)_3\text{N}$ according to a procedure similar to that in Example 3 to give the primary amine.

30 Step 3: Treat the product of Step 2 (150 mg) in CH_2Cl_2 (3 mL) with methyl isocyanate (14.7 mg) and stir for 1 h. Evaporate the solvent and purify by silica gel chromatography using CH_2Cl_2 / CH_3OH saturated with ammonia to provide 137 mg (86%) of the title compound.

Example 17N:

35 Step 1: Cool a solution of Example 17J (1.0g) in CH_2Cl_2 (20 mL) and then treat with NEt_3 (507 μL) and mesyl chloride (170 μL). Warm the solution to 0 °C and stir for 30 min. Pour into EtOAc / NaHCO_3 . Wash the

- 45 -

organic layer with H₂O, brine and dry (Na₂SO₄). Remove the solvent to provide the mesylate (quantitative).

Step 2: Treat a solution of the product of Step 1 in dry DMF with NaSCH₃. Stir the solution for 45 min, then pour the mixture into EtOAc /

- 5 aqueous NaHCO₃. Wash the organic layer with H₂O and brine, dry (Na₂SO₄) and purify by silica gel chromatography using EtOAc / NEt₃ to provide 282 mg (86%) of the methyl sulfide.

- Step 3: Dissolve the product of Step 2 (64 mg) in THF (2 mL) and treat with *t*-butanol (500 µL), osmium tetroxide (56 µL of 2.5% solution in *t*-butanol), and NMO (31.6 mg) and stir the mixture for 2 h at 23 °C. Pour the mixture into EtOAc / aqueous NaHSO₄. Wash the organic layer with saturated aqueous NaHCO₃ and brine, dry (Na₂SO₄), filter, concentrate and purify by silica gel chromatography using EtOAc / NEt₃ to provide 57 mg (85%) of the title compound.

- 15 **Example 17O**: Alkylate and deprotect the product of Example 17A according to a procedure similar to Example 17J substituting 2-bromo-1-*t*-butyldimethylsilyloxy ethane for 3-bromo-1-*t*-butyldimethylsilyloxy propane. Convert the product to the methyl sulfone according to a procedure similar to that described in Example 17N.

- 20 **Example 17P**: Dissolve the product of Example 17N Step 2 (128 mg) in CH₂Cl₂ (5 mL) and treat with ReOCl₃(PPh₃)₄ (7.5 mg) and phenyl sulfoxide (51 mg). Stir for 3 h at 23 °C, then add ReOCl₃(PPh₃)₄ (7.5 mg) and phenyl sulfoxide (51 mg) and stir at 23 °C for 15 h. Add H₂O (20 mL) and extract with CH₂Cl₂. Dry the organic layer with MgSO₄ and
- 25 concentrate. Purify using silica gel chromatography (EtOAc/NEt₃/CH₃OH as eluant) to provide 95 mg (72%) of the title compound.


Example 17Q: Alkylate the product of Example 17A with the product of Example 18L, Step 2, using a procedure similar to that described in Example 18L, Step 3, to obtain the title compound.

- 30 **Example 17R**: Treat the product of Example 17L with excess diazomethane in Et₂O to obtain the title compound.

Example 17S: Alkylate the product of Example 17A using a procedure similar to that described in Example 2 using BrCH₂F in place of methyl bromoacetate to obtain the title compound.

- 35 **Example 17T**: Treat the product of Example 17D according to a procedure similar to that of Example 18M to obtain the title compound.

- 46 -

Example 18

Example	R¹	MS (FAB): m/e
18A	H	587 (M+1)
18B	CH₃	601 (M+1)
18C	CH₂CH₂OH	631 (M+1)
18D	CH₂CN	626 (M+1)
18E		659 (M+1)
18F		728 (M+1)
18G	CH₂CH₂CH₂OH	645 (M+1)
18H		714 (M+1)
18I		728 (M+1)
18J		730 (M+1)
18K		727 (M+1)
18L		674 (M+1)
18M		673 (M+1)
18N		688 (M+1)

Example 18A:

- Step 1: Treat the product of Preparation 7 using a procedure similar to that described in Example 6, Step 8. Proceed in a similar manner as described in Example 9, Steps 8-9, using the product of Preparation 3O6

- 47 -

in place of 4-phenylamino-piperidine. Proceed in a manner similar to the procedure outlined in Preparation 2, Step 4, optionally substituting HCl for TFA. Acylate the amine according to a procedure similar to Preparation 2, Step 2A, using 3,5-dimethylbenzoyl chloride.

- 5 **Step 2:** Treat the resultant product using a procedure similar to Example 5, Step 4, to obtain the title compound.

Alternatively, for the preparation of optically active material, treat the product derived from a procedure similar to that of Preparation 6, Steps 1 and 2, substituting 3,5-dimethylbenzoyl chloride for 3,5-dichlorobenzoyl chloride in Step 1 and resolving the product of Step 2 in a procedure similar to that described in Preparation 6, Step 4B. Continue with the procedure outlined in Example 11, Step 5, followed by the procedure of Example 13D, Step 2.

- 15 **Example 18B:** Alkylate Example 18A with CH₃I according to a procedure similar to Example 2 to give the title compound.

Example 18C: Alkylate and deprotect the product of Example 18A using a procedure similar to Example 2B to give the title compound.

Example 18D: Alkylate Example 18A with BrCH₂CN according to a procedure similar to Example 2A to give the title compound.

- 20 **Example 18E:** Use a procedure similar to that described in Example 4 using the product of 18D to obtain the title compound.

Example 18F:

Step 1: Alkylate Example 18A with allylchloroacetate according to a procedure similar to Example 2 to give the allyl ester.

- 25 Step 2: Deprotect the product of Step 1 using a procedure similar to Example 5, Step 4.

Step 3: Couple the product of Step 2 with 2-amino-1,3,4-thiadiazole using a procedure similar to Example 15G, Step 2 to give the title compound.

- 30 **Example 18G:** Alkylate Example 18A with 3-bromo-1-t-butyldimethylsilyloxy propane and deprotect using a procedure similar to that described in Example 2B to obtain the title compound.

- Example 18H:** Treat the product of Example 18F, Step 1, with morpholine at 65 °C using a procedure similar to that in Example 3 to give the title compound.

Example 18I: Treat the product of Example 18F, Step 1, at 23 °C with n-methylpiperazine using a procedure similar to that in Example 3 to give the title compound.

- 48 -

Example 18J: Couple the product of Example 18F, Step 2, with thiomorpholine using a procedure similar to that in Example 8 to give the title compound.

Example 18K: Couple the product of Example 18F, Step 2, with 2-aminothiazole using a procedure similar to that in Example 18F, Step 3, to give the title compound.

Example 18L:

Step 1: Treat a solution of $\text{CH}_3\text{ONH}_2 \cdot \text{HCl}$ (2.5g) in H_2O (40 mL) with NaHCO_3 (5g). Cool to 0°C and add a solution of ClCH_2COCl (2.4 mL) in THF (20 mL) at a rate to maintain the internal temperature at $0-3^\circ\text{C}$. Upon complete addition, warm to 23°C and stir for 2 h. Adjust pH to 5 (Na_2CO_3), remove THF in vacuo, add NaCl and extract with CH_2Cl_2 . Dry the organic layer (Na_2SO_4), filter and concentrate to give the α -chloroamide.


Step 2: Treat a solution of the product of Step 1 (131 mg) in acetone (1 mL) with NaI (158 mg). Stir for 7 h at 23°C , remove the solvent in vacuo, redissolve in THF, filter through Celite and concentrate to give the iodoamide.

Step 3: Alkylate Example 18A with the product of Example 18L, Step 2, using a procedure similar to that described in Example 2 using 2.5 eq. of NaH to obtain the title compound.

Example 18M: Use a procedure similar to that described in Example 4 using the product of 18D and the following modifications: substitute $\text{CH}_3\text{ONH}_2 \cdot \text{HCl}$ for $\text{HONH}_2 \cdot \text{HCl}$, use 2,2,2-trifluoroethanol as the solvent, and stir at 70°C for 1 week to obtain the title compound.




Example 18N: Treat the product of 18C according to a procedure similar to Example 17M, Step 3.

Example 19



Example	R1	MS (FAB): m/e
19A	H	672 (M+1)
19B	CH_2CN	711 (M+1)

- 49 -

19C		744 (M+1)
19D		813 (M+1)
19E		759 (M+1)

Example 19A:

Step 1: Treat the product of Preparation 7 using a procedure similar to that described in Example 6, Step 8. Proceed in a similar manner to Example 9, Steps 8-9, using the product of Preparation 5A or 3A6 in place of 4-phenylamino-piperidine. Proceed in a manner similar to the procedure outlined in Preparation 2, Step 4, optionally substituting HCl for TFA. Acylate the amine according to a procedure similar to Preparation 2, Step 2A, using 3,5-dimethylbenzoyl chloride.

Step 2: Treat the product of Step 1 using a procedure similar to Example 5, Step 4, to obtain the title compound.

Alternatively, for the preparation of optically active material, treat the product derived from a procedure similar to that of Preparation 6, Steps 1 and 2, substituting 3,5-dimethylbenzoyl chloride for 3,5-dichlorobenzoyl chloride in Step 1 and resolving the product of Step 2 in a procedure similar to that described in Preparation 6, Step 4B. Continue with the procedure outlined in Example 11, Step 5, followed by the procedure of Example 13A, Step 2.

Example 19B: Alkylate the product in Example 19A with BrCH₂CN using a procedure similar to Example 2A to give the title compound.

Example 19C: Use a procedure similar to that described in Example 4 using the product of Example 19B to obtain the title compound.

Example 19D:


Step 1: Alkylate the product in Example 19A with allylchloroacetate according to a procedure similar to Example 2 to give the allyl ester.

Step 2: Treat the product of Step 1 using a procedure similar to Example 5, Step 4.

Step 3: Couple the product of Step 2 with 2-amino-1,3,4-thiadiazole according to a procedure similar to Example 15G, Step 2, to give the title compound.

Example 19E: Alkylate the product of Example 19A with the product of Example 18L, Step 2, using a procedure similar to that described in Example 2 using 2.5 eq. of NaH to obtain the title compound.

- 50 -

Example 20

Example	R ¹	MS (FAB): m/e
20A		686 (M+1)
20B	CH ₂ CH ₂ OH	658 (M+1)

Example 20A:


Step 1: Treat the product of Preparation 7 using a procedure similar to that described in Example 6, Step 8. Proceed in a similar manner to Example 9, Steps 8-9, using 4-hydroxy-4-phenylpiperidine in place of 4-phenylamino-piperidine. Proceed in a manner similar to the procedure of Preparation 2, Step 4, optionally substituting HCl for TFA. Acylate the amine according to a procedure similar to Preparation 2, Step 2A, using 3,5-dimethoxybenzoyl chloride.

Step 2: Treat the product of Step 1 using a procedure similar to Example 5, Step 4.

Step 3: Alkylate the product of Step 2 with BrCH₂CN according to a procedure similar to Example 2A to give the title compound.

Step 4: Use a procedure similar to that described in Example 4 using the product of Step 3 to obtain the title compound.

Example 20B: Alkylate the product of Example 20A, Step 2 with 2-bromo-1-t-butyldimethylsilyloxy ethane and deprotect using a procedure similar to that described in Example 2B to obtain the title compound.

Example 21

Example	R ¹	MS (FAB): m/e
21A	CH ₂ CN	672 (M+1)
21B		705 (M+1)

- 51 -


Example 21A:

Step 1: Treat the product of Preparation 7 using a procedure similar to that described in Example 6, Step 8. Proceed in a similar manner as described in Example 9, Steps 8-9, using the product of Preparation 3O6 in place of 4-phenylamino-piperidine. Proceed in a manner similar to the procedure outlined in Preparation 2, Step 4, optionally substituting HCl for TFA. Acylate the amine according to a procedure similar to Preparation 2, Step 2A, using 4-methyl-3,5-dimethoxybenzoyl chloride.

Step 2: Treat the product of Step 1 using a procedure similar to Example 5, Step 4.


Step 3: Alkylate the product of Step 2 with BrCH_2CN using a procedure similar to Example 2A to give the title compound.

Example 21B: Treat the product of Example 21A using a procedure similar to that described in Example 4 to obtain the title compound.

Example 22


Use a procedure similar to that described in Example 20A using the product of Preparation 3O6 in place of 4-hydroxy-4-phenylpiperidine in Step 1 to obtain the title compound. HRMS (FAB, $\text{M}+\text{H}^+$): m/e calc'd:

691.2778, found 691.2769.


Example 23

Use a procedure similar to that described in Example 20A using 3,4,5- trimethoxybenzoyl chloride as the acid chloride in Step 1 to obtain the title compound; MS (FAB): m/e 716 ($\text{M}+1$).


- 52 -

Example 24


Use a procedure similar to that described in Example 11, using the product of Preparation 3O6 as the amine in Step 6 to obtain the title compound. HRMS (FAB, $M+H^+$): m/e calc'd: 709.2147 found 709.2138.

Example 25

Using a procedure similar to that of Example 2, methylate product of Example 3H5, replacing methyl iodide with methylbromoacetate. Deprotect the resulting product and couple to the product of Example 12, Step 1, using the procedure of Example 9, Step 9, to obtain the title compound. HRMS (FAB, $M+H^+$): m/e calc'd: 798.2537; found 798.2538.

Example 26


Use a procedure similar to that described in Example 17B using 3-chloro-5-methyl-benzoyl chloride instead of 3,5-dichlorobenzoyl chloride (Step 1, Example 17A) to obtain the title compound. HRMS (FAB, $M+H^+$): m/e calc'd: 621.2166, found 621.2178

Example 27

Use a procedure similar to that described in Example 13A using 3-

- 53 -

chloro-5-methyl-benzoyl chloride instead of 3,5-dichlorobenzoyl chloride to obtain the title compound. HRMS (FAB, $M+H^+$): m/e calc'd: 706.2694, found 706.2701

Example 28

5


Step 1: Condense glycine with 3,5-dichlorobenzoic acid according to a procedure similar to Example 8. Treat the resulting amide with NaH followed by iodoethane according to Example 2. Treat the resulting material with diazomethane to give N-ethyl-N-(3,5-dichlorobenzoyl)-glycine methyl ester.

10

Step 2: Using the procedures of Example 11, Steps, 2-5, substituting the product of Step 1 for the product of Example 11, Step 1. Optically active material may be prepared using procedures similar to Preparation 6.

The following compounds are prepared by reacting the product of Step 2 with an appropriate amine (for 28A to 28C, see Preparation 5A-5C; for 28D, see Preparation 3O6) according to a procedure similar to Example 9, Step 9, substituting $NaB(OAc)_3H$ for $NaBH_3CN$ and optionally substituting 1,2-dichloroethane for 2,2,2-trifluoroethanol.


15



Example	Z	Data
28A		--
28B		MS (FAB): m/e 728 ($M+1$)
28C		HRMS: calc'd: 712.1991 found: 712.1986
28D		--

20

- 54 -

Example 29


- Step 1:** Add carbonyldiimidazole (24 g) to a solution of allyl -3,4-dichlorophenyl acetic acid (30.6 g) in anhydrous THF (600 mL). Stir the reaction mixture at 23 °C for 1 hr. In a separate flask, under N₂, dissolve potassium t-butoxide (16.8 g) in anhydrous THF (425 mL). Cool the solution to 0 °C and add CH₃NO₂ (200 mL) over 30 min. Add the acyl imidazole solution to the potassium nitronate solution *via* addition funnel while keeping the internal temperature between 0°C and 5°C. Remove the cooling bath and stir at 23°C for 2 days. Cool the reaction mixture to 0°C and pour into cold 1M HCl (500 mL). Separate the organic layer, dry (MgSO₄) and concentrate to give 34 g of orange oil. MS (Cl+/CH₄) m/e 288 (M+1).
- Step 2:** Cool a solution of the product of Step 1 (12.2 g) in THF (34 mL) and HOAc (34 mL) to 0 °C and add H₂O (17 mL). Add powdered Zn (15.6 g) in portions over 15 min. Stir the reaction mixture 15 min at 0 °C then warm to 23 °C. Heat the reaction mixture to 40 °C for 3 min. Remove the heat and pour into H₂O (150 mL) and THF (100 mL). Filter the mixture and wash the solids with THF and H₂O. Concentrate the filtrate and wash the resulting orange material with Et₂O and CH₂Cl₂. Concentrate the filtrate to give 15.5 g orange oil. MS (Cl +/CH₄) m/e 259 (M+1).
- Step 3:** Cool a solution of the product of Step 2 (15.5 g) in THF (55 mL) and H₂O (10 mL) to 0 °C and add 3,5-dichlorobenzoyl chloride (8.2 g), Hunig's base (12 mL) and DMAP (0.25 g). Warm the reaction mixture to 23 °C and stir for 16 h. Add EtOAc (300 mL) and wash with H₂O (30 mL), 1M HCl (3 x 30 mL), H₂O (2 x 30 mL) and brine (2 x 40 mL), dry (MgSO₄), and concentrate. Purify (SiO₂; elute with gradient of 4% EtOAc/hexanes to 25% EtOAc/hexanes) to give 8.8 g of a solid. MS (Cl+/CH₄) m/e 432 (M+ 1).
- Step 4:** Treat a solution of the product of Step 3 (5.7 g, 13 mmol) in EtOH (100 mL) and H₂O (25 mL) with CH₃ONH₂•HCl (5.54 g, 66.3 mmol) and stir at 23 °C for 2 days. Concentrate the mixture and add EtOAc (200 mL) and H₂O (20 mL). Separate the layers and wash the organic layer with

- 55 -

1M NaHCO₃ (2 x 20 mL) and brine (20 mL), dry (MgSO₄) and concentrate to an oil. Purify (SiO₂; elute with a gradient of 4% EtOAc/hexanes to 15% EtOAc/hexanes to give 1.8 g of clear oil. MS (CI+/CH₄) m/e 461 (M+1)


- 5 Step 5: Treat the product of Step 4 according to a procedure similar to Example 11, Step 5, to obtain the title compound. MS (FAB): m/e 464 (M+1).

10 The following compounds of formula 29A to 29D are prepared by reacting the product of Step 5 with an appropriate amine (for 29A to 29C, see Preparation 5A-5C; for 29D, see Preparation 3O6) according to a procedure similar to Example 9, Step 9.



Example	Z	MS (FAB): m/e
29A		--
29B		700 (M+1)
29C		686 (M+1)
29D		629 (M+1)


No Sch #

Example 30

- 15 Treat the crude product from Example 7, Step 1, (1.65 g) with CH₃NH₂ according to a procedure similar to Example 7, Step 2, to give the desired product (0.6 g). MS(FAB): m/e 464.

- 56 -


Treat the product from Step 1 with the appropriate carboxylic acid according to a procedure similar to Example 8 to give the following compounds:



Example	Carboxylic Acid	XT	MS(FAB): m/e
30A			617 (M+1)
30B			597 (M+1)
30C			637 (M+1)
30D			626 (M+1)
30E			633 (M+1)
30F			658 (M+1)
30G			628 (M+1)

- 57 -

30H			596 (M+1)
30I			600 (M+1)

Example 31

Step 1: Treat the product of Preparation 7 according to a procedure similar to that described in Example 6, Step 8. Proceed in a similar manner as described in Example 9, Steps 8-9, using 4-phenyl-4-hydroxypiperidine in place of 4-phenylamino-piperidine.


Step 2: Treat the product of Step 1 using a procedure similar to Example 5, Step 4.

Step 3: Treat the product of Step 2 in a similar procedure to that of Preparation 2, Step 4.

Step 4: Treat the product of Step 3 (8.4 g) with 2-chloro-6-methylpyridine-4-carboxylic acid (3.84 g), according to a procedure similar to Example 8 to give product (5.9 g).


Step 5: Treat the product of Step 4 (3.65 g) with BrCH_2CN (0.725 g) according to a procedure similar to Example 2A to give the product (1.9 g).

Step 6: Treat the product of Step 5, (1.8 g) using a procedure similar to Example 4, to give the title compound (1.31 g). MS(FAB): m/e 675 (M+1).

Example 32

- 58 -


Alkylate and deprotect the product of Example 31, Step 4, using a procedure similar to Example 2B, to give the product. MS(FAB): m/e 647 (M+1).

Example 33


5

The title compound is prepared in a similar manner to the procedures of Example 32 by substituting 2-chloro-6-methylpyridine-4-carboxylic acid with 2-(dimethylamino)-6-methylpyridine-4-carboxylic acid and the product of Preparation 3O6 for 4-hydroxy-4-phenyl piperidine.

10 MS(FAB): m/e 661 (M+1).


Example 34

15 Treat the crude product from Example 7, Step 1, according to a procedure similar to Example 30, substituting NH_4OAc for MeNH_2 in Step 1 and using 3,5-bis(trifluoromethyl)benzoic acid in Step 2 to give the title compound. MS(FAB): m/e 690.

Example 35

20 Use a procedure similar to that described in Example 18B using the product of Preparation 5B in place of the product of Preparation 3O6 to obtain the title compound. HRMS (FAB): m/e 672 (M+1).

- 59 -

Example 36

- Step 1: 4-Piperidone hydrochloride (50 g) in saturated NaHCO_3 solution (1L) was treated with a dioxane (30 mL) solution of benzyloxycarbonyl-chloride (53.4 mL). The solution was stirred for 18 h at room temperature then extracted with EtOAc (2 x 500 mL). The organic fractions were combined, washed with 1N HCl (500 mL) and brine (500 mL), dried over MgSO_4 , filtered and evaporated to afford 1-benzyloxycarbonyl-4-piperidone (75 g).
- Step 2: 2-Bromothioanisole (13.7 g) in TMF (120 mL) was cooled to -78°C (internal temperature) and treated with *n*-BuLi (36.5 mL, 2.5 M hexane solution). After 10-15 min., a THF (120 mL) solution of the product of Step 1 (12.5 g), also at -78°C , was added via a cannula. The combined mixture was stirred for a further 18 h, during which time it warmed to room temperature. The solution was treated with saturated NH_4Cl solution (250 mL), EtOAc (250 mL) and the organic layer separated. The aqueous portion was extracted with additional EtOAc (2 x 250 mL). The organic extracts were combined, washed with H_2O (250 mL) and brine (250 mL), dried over MgSO_4 , filtered and evaporated to give an oil. Silica gel chromatography, eluting with EtOAc/hexane mixtures, gave 1-benzyloxycarbonyl-4-hydroxy-4-(2-methylthiophenyl)piperidine (9.61 g).
- Step 3: The product of Step 2 (5.1 g) in CH_2Cl_2 (50 mL) was treated sequentially with trifluoroacetic acid (8.9 mL) and triethylsilane (34.5 mL). After 18 h, the solution was treated with saturated NaHCO_3 (150 mL). After a further 1 h, the organic layer was separated and the aqueous extracted with CH_2Cl_2 (100 mL). The organic extracts were combined, dried over Na_2SO_4 , filtered and evaporated. The crude product was purified by silica gel chromatography, eluting with EtOAc/hexane mixtures to give 1-benzyloxycarbonyl-4(2-methylthiophenyl)piperidine (3.3 g).
- Step 4: The product of Step 3 (2.55 g) in CH_2Cl_2 (30 mL) was cooled to 0°C and treated with mCPBA (60%, 2.16 g) and stirred for 1 h. The reaction mixture was treated with ice (20 g), saturated NH_4OH solution (20 mL) and stirred for 10 minutes. The organic layer was separated and the aqueous layer re-extracted with CH_2Cl_2 (2 x 30 mL). The combined

- 60 -


organic portions were dried over MgSO_4 , filtered and evaporated to give a gum. Silica gel chromatography, eluting with $\text{EtOAc}/\text{CH}_2\text{Cl}_2$ mixtures, gave 1-benzyloxycarbonyl-4-(2-methylsulfinylphenyl)piperidine (0.5 g).

5 Step 5: The product of Step 4 (0.5 g) was treated with trifluoroacetic acid (10 mL) and heated at reflux temperature for 45 minutes. The reaction mixture was cooled, diluted with toluene (40 mL) and evaporated. This procedure was repeated two more times. The residue was treated with CH_2Cl_2 (70 mL) and adjusted to alkaline pH via addition of NH_4OH solution. The organic layer was separated, dried over MgSO_4 , filtered and
10 evaporated to give 4-(2-methylsulfinylphenyl)piperidine (0.3 g).

Step 6: Using a procedure similar to Example 9, Step 9, the product of Step 5 is coupled to the appropriate O-methyloxime to obtain the title compound. Mass Spec (FAB) 684 (100%).

15 Using the procedures of Steps A through E of Example 36, starting with 3-bromothioanisole and 4-bromothioanisole, the corresponding 4-(3-methylsulfinylphenyl)piperidine and 4-(4-methylsulfinylphenyl)piperidines were obtained.

Example 37



20 Step 1: Treat the product of Preparation 7 as described in Example 20A, acylating the amine using 3,4,5-trimethoxybenzoyl chloride.

Step 2: Treat the product of Step 1 using a procedure similar to Example 5, Step 4.

25 Step 3: Alkylate the product of Step 2 with BrCH_2CN according to a procedure similar to Example 2A.

Step 4: Treat a solution of the product of Step 3 (2.5 g) in CH_3OH (37 mL) with NaOCH_3 (200 mg). Stir for 18 h. Treat the resulting solution with $\text{CH}_3\text{ONH}_2\cdot\text{HCl}$ and stir for 3 h. Remove the solvent and re-suspend in CH_2Cl_2 , dry over MgSO_4 , filter, concentrate in vacuo and purify by silica
30 gel chromatography (5 x 20 cm; 5% $\text{CH}_3\text{OH}/\text{CH}_2\text{Cl}_2$) to give 2.2 g of the desired product as a white foam. HRMS (FAB) 730.2774 ($\text{M}+\text{H}^+$).

- 61 -

The following formulations exemplify some of the dosage forms of this invention. In each, the term "active compound" refers to a compound of formula I.

EXAMPLE A

5

Tablets

<u>No.</u>	<u>Ingredient</u>	<u>mg/tablet</u>	<u>mg/tablet</u>
1	Active Compound	100	500
2	Lactose USP	122	113
3	Corn Starch, Food Grade, as a 10% paste in Purified Water	30	40
4	Corn Starch, Food Grade	45	40
5	Magnesium Stearate	<u>3</u>	<u>7</u>
	Total	300	700

Method of Manufacture

- Mix Item Nos. 1 and 2 in suitable mixer for 10-15 minutes. Granulate the mixture with Item No. 3. Mill the damp granules through a coarse screen (e.g., 1/4", 0.63 cm) if necessary. Dry the damp granules.
- 10 Screen the dried granules if necessary and mix with Item No. 4 and mix for 10-15 minutes. Add Item No. 5 and mix for 1-3 minutes. Compress the mixture to appropriate size and weight on a suitable tablet machine.

EXAMPLE BCapsules

<u>No.</u>	<u>Ingredient</u>	<u>mg/tablet</u>	<u>mg/tablet</u>
1	Active Compound	100	500
2	Lactose USP	106	123
3	Corn Starch, Food Grade	40	70
4	Magnesium Stearate NF	<u>4</u>	<u>7</u>
	Total	250	700

15 Method of Manufacture

Mix Item Nos. 1, 2 and 3 in a suitable blender for 10-15 minutes. Add Item No. 4 and mix for 1-3 minutes. Fill the mixture into suitable two-piece hard gelatin capsules on a suitable encapsulating machine.

20

EXAMPLE CSterile Powder for Injection

<u>Ingredient</u>	<u>mg/vial</u>	<u>mg/vial</u>
Active sterile powder	100	500

For reconstitution add sterile water for injection or bacteriostatic water for injection.

- 62 -

The *in vitro* and *in vivo* activity of the compounds of formula I can be determined by various procedures known in the art, such as a test for their ability to inhibit the activity of the NK₁ agonist Substance P, an isolated hamster trachea NK₂ assay, a test of the effect of NK₁ antagonists on Substance P-induced airway microvascular leakage, measurement of NK₂ activity *in vivo* in guinea pigs, measurement of bronchoconstriction due to NKA, and neurokinin receptor binding assay(s). Typical procedures are described in WO96/34857, published November 7, 1996. NK₃ activity is determined by following a procedure similar to that described in the literature, e.g., *Molecular Pharmacol.*, 48 (1995), p. 711-716.

% Inhibition is the difference between the percent of maximum specific binding (MSB) and 100%. The percent of MSB is defined by the following equation, wherein "dpm" is disintegrations per minute:

$$\% \text{ MSB} = \frac{(\text{dpm of unknown}) - (\text{dpm of nonspecific binding})}{(\text{dpm of total binding}) - (\text{dpm of nonspecific binding})} \times 100$$

It will be recognized that compounds of formula I exhibit NK₁, NK₂ and/or NK₃ antagonist activity to varying degrees, e.g., certain compounds have strong NK₁ antagonist activity, but weaker NK₂ and NK₃ antagonist activity, while others are strong NK₂ antagonists, but weaker NK₁ and NK₃ antagonists. While compounds with approximate equipotency are preferred, it is also within the scope of this invention to use compounds of with unequal NK₁/NK₂/NK₃ antagonist activity when clinically appropriate.





Preferred compounds of the genus of this invention have a K_i ≤ 10nM for the NK₁ receptor. Also preferred are compounds of formula I having a K_i ≤ 10nM for the NK₂ receptor. Also preferred are compounds having a K_i ≤ 10nM for each of the NK₁ and NK₂ receptors. More preferred are compounds having a K_i ≤ 2nM for the NK₁ receptor and a K_i ≤ 2nM for the NK₂ receptor. Compounds of the invention tested for NK₃ have K_i's in the range of 0.05 to 50nM. The compound of Example 11, the only amide specifically disclosed in U.S. 5,696,267, has a K_i of 3.6 for the NK₁ receptor and a K_i of 9.2 for the NK₂ receptor.


Using the test procedures described above, the exemplified compounds were found to have K_i values in the range of 0.2 to 6 nM, preferably 0.2 to 1 nM, for the NK₁ receptor, and K_i values in the range of 0.2 to 2.7 nM, preferably 0.2 to 1 nM, for the NK₂ receptor.

- 63 -




What is claimed:

1. A compound selected from the group consisting of











- 65 -




5




- 66 -



- 67 -




- 68 -




5

- 69 -






and




and diastereomers, enantiomers, rotational isomers, E and Z isomers of the oxime, and pharmaceutically acceptable salts thereof.




- 5 2. A compound of claim 1 selected from the group consisting of




- 70 -




- 71 -




5




- 72 -




3. A compound of claim 2 selected from the group consisting of




5



- 73 -




5 4. A compound of claim 1 which is



or a diastereomer, enantiomer, rotational isomer, E and Z isomer of the oxime, or pharmaceutically acceptable salt thereof.

- 74 -


5. A compound represented by the formula



or a diastereomer, enantiomer, rotational isomer or E or Z isomer of the oxime, or a pharmaceutically acceptable salt, thereof, wherein:

5 T is R²-phenyl or R³-pyridyl;

R¹ is H, methyl, ethyl, -CH₂CN, -CH₂C(O)NH₂, -(CH₂)₃SO₃H, -CH₂C(O)NHCH₃, -CH₂C(O)NHOH, -CH₂C(O)NHOCH₃, -CH₂C(O)NHCH₂CN, -CH₂F, -CH₂C(O)NHCH₂SO₃H,




10 R² is 2-3 substituents independently selected from the group consisting of chloro, methyl and methoxy;

R³ is 2 to 3 substituents independently selected from the group consisting of chloro and methyl;


R⁴ is methyl or ethyl; and

15 Z is




20

- 75 -




6. A compound of claim 5 wherein T is R^2 -substituted phenyl, wherein R^2 is two chloro substituents, two methyl substituents or two methoxy and one methyl substituent; R^1 is methyl, $-\text{CH}_2\text{F}$, $-\text{CH}_2\text{CN}$,

5 $-\text{CH}_2\text{C}(\text{O})\text{NHCH}_2\text{SO}_3\text{H}$, N^-OH or N^-OCH_3 ; R^4 is methyl; and



10

7. A compound of claim 6 wherein R^2 is two chloro substituents, R^1 is methyl and Z is



INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 98/23255

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C07D211/76 C07D211/52 C07D401/12 A61K31/445

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	EP 0 630 887 A (ZENECA LIMITED) 28 December 1994 see the whole document ---	1,5
A	WO 96 39386 A (SCHERING CORPORATION) 12 December 1996 see the whole document ---	1,5
A	WO 96 34857 A (SCHERING CORPORATION) 7 November 1996 cited in the application see the whole document ---	1,5
A	WO 95 12577 A (ZENECA LIMITED) 11 May 1995 see the whole document ---	1,5
-/--		

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

16 April 1999

Date of mailing of the international search report

23/04/1999

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Kyriakakou, G

INTERNATIONAL SEARCH REPORT

Intern. Patent Application No

PCT/US 98/23255

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 95 05377 A (ZENECA LIMITED) 23 February 1995 see the whole document -----	1,5
A	WO 94 10146 A (ZENECA LIMITED) 11 May 1994 see the whole document -----	1,5
A	US 5 350 852 A (XAVIER EMONDS-ALT ET AL.) 27 September 1994 cited in the application see the whole document -----	1,5

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 98/23255

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 630887 A	28-12-1994	AU 673063 B	24-10-1996
		AU 6320394 A	15-12-1994
		CA 2124048 A	25-11-1994
		CN 1098094 A	01-02-1995
		FI 942381 A	25-11-1994
		HU 70445 A	30-10-1995
		IL 109734 A	24-09-1998
		IL 120895 A	24-09-1998
		JP 6340625 A	13-12-1994
		NO 941906 A	25-11-1994
		NZ 260566 A	26-07-1996
		US 5654299 A	05-08-1997
WO 9639386 A	12-12-1996	US 5654316 A	05-08-1997
		AU 5950996 A	24-12-1996
		CA 2198238 A	12-12-1996
		EP 0773929 A	21-05-1997
		HU 9701281 A	28-11-1997
		NZ 309369 A	24-09-1998
WO 9634857 A	07-11-1996	AU 5714096 A	21-11-1996
		CA 2218913 A	07-11-1996
		CZ 9703424 A	15-07-1998
		EP 0823896 A	18-02-1998
		HU 9800840 A	28-08-1998
		JP 10506923 T	07-07-1998
		NO 975029 A	30-12-1997
		PL 323088 A	02-03-1998
		SK 147197 A	05-08-1998
		US 5696267 A	09-12-1997
		US 5688960 A	18-11-1997
		US 5840725 A	24-11-1998
WO 9512577 A	11-05-1995	AU 8000594 A	23-05-1995
		CA 2172377 A	11-05-1995
		EP 0726893 A	21-08-1996
		JP 9505036 T	20-05-1997
		US 5534525 A	09-07-1996
		US 5677317 A	14-10-1997
WO 9505377 A	23-02-1995	AT 172971 T	15-11-1998
		AU 677091 B	10-04-1997
		AU 7388094 A	14-03-1995
		CA 2166800 A	23-02-1995
		CN 1129449 A	21-08-1996
		CZ 9600434 A	15-05-1996
		DE 69414398 D	10-12-1998
		EP 0714392 A	05-06-1996
		ES 2123810 T	16-01-1999
		FI 960727 A	16-02-1996
		HU 75113 A	28-04-1997
		JP 9501439 T	10-02-1997
		NO 960630 A	16-02-1996
		NZ 269575 A	24-11-1997
		PL 313075 A	27-05-1996
		SK 21096 A	05-02-1997
		US 5567700 A	22-10-1996
		US 5861392 A	19-01-1999

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 98/23255

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9505377 A		ZA 9406142 A	17-02-1995
WO 9410146 A	11-05-1994	AU 5374294 A	24-05-1994
		CN 1094723 A	09-11-1994
		EP 0667858 A	23-08-1995
		EP 0897913 A	24-02-1999
		JP 8502511 T	19-03-1996
		MX 9306821 A	29-07-1994
		US 5576333 A	19-11-1996
		US 5559131 A	24-09-1996
		US 5559132 A	24-09-1996
		ZW 13893 A	27-07-1994
		ZA 9307915 A	03-05-1994
US 5350852 A	27-09-1994	FR 2666335 A	06-03-1992
		FR 2678267 A	31-12-1992
		AT 174332 T	15-12-1998
		AU 657272 B	09-03-1995
		AU 8354291 A	12-03-1992
		CA 2050639 A,C	06-03-1992
		CS 9102724 A	18-03-1992
		DE 69130597 D	21-01-1999
		EP 0474561 A	11-03-1992
		FI 914174 A,B,	06-03-1992
		HU 9500521 A	30-10-1995
		IL 99320 A	31-07-1995
		JP 2620435 B	11-06-1997
		JP 4261155 A	17-09-1992
		LT 585 A,B	27-12-1994
		LV 10606 A	20-04-1995
		LV 10606 B	20-04-1996
		NO 177226 B	02-05-1995
		NZ 239661 A	27-06-1994
		PL 167994 B	30-12-1995
		PT 98849 A	31-07-1992
		SG 47703 A	17-04-1998
		RU 2070196 C	10-12-1996
		US 5236921 A	17-08-1993
		MX 9102003 A	01-12-1992